WO2012092411A2 - Phenanthridine macrocyclic hepatitis c serine protease inhibitors - Google Patents

Phenanthridine macrocyclic hepatitis c serine protease inhibitors Download PDF

Info

Publication number
WO2012092411A2
WO2012092411A2 PCT/US2011/067701 US2011067701W WO2012092411A2 WO 2012092411 A2 WO2012092411 A2 WO 2012092411A2 US 2011067701 W US2011067701 W US 2011067701W WO 2012092411 A2 WO2012092411 A2 WO 2012092411A2
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
replicon
compound
alkyl
heteroatoms selected
Prior art date
Application number
PCT/US2011/067701
Other languages
French (fr)
Other versions
WO2012092411A3 (en
Inventor
Keith F. Mcdaniel
Hui-Ju Chen
Jason P. Shanley
David J. Grampovnik
Brian Green
Timothy MIDDLETON
Todd Hopkins
Yat Sun Or
Original Assignee
Enanta Pharmaceuticals, Inc.
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46383854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2012092411(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CN201180068287.6A priority Critical patent/CN103380132B/en
Priority to EP11853433.8A priority patent/EP2658858A4/en
Priority to AU2011352145A priority patent/AU2011352145A1/en
Priority to CA2821340A priority patent/CA2821340A1/en
Priority to BR112013016480A priority patent/BR112013016480A2/en
Application filed by Enanta Pharmaceuticals, Inc., Abbott Laboratories filed Critical Enanta Pharmaceuticals, Inc.
Priority to KR1020137020148A priority patent/KR20140003521A/en
Priority to SG2013049416A priority patent/SG191759A1/en
Priority to EA201390988A priority patent/EA201390988A1/en
Priority to JP2013547656A priority patent/JP2014506255A/en
Priority to MX2013007698A priority patent/MX2013007698A/en
Publication of WO2012092411A2 publication Critical patent/WO2012092411A2/en
Publication of WO2012092411A3 publication Critical patent/WO2012092411A3/en
Priority to ZA2013/04579A priority patent/ZA201304579B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • the present invention relates to novel macrocycles having activity against the hepatitis C virus (HCV) and useful in the treatment of HCV infections. More particularly, the invention relates to macrocyclic compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
  • HCV hepatitis C virus
  • HCV is the principal cause of non-A, non-B hepatitis and is an increasingly severe public health problem both in the developed and developing world. It is estimated that the virus infects over 200 million people worldwide, surpassing the number of individuals infected with the human immunodeficiency virus (HIV) by nearly five fold. HCV infected patients, due to the high percentage of individuals inflicted with chronic infections, are at an elevated risk of developing cirrhosis of the liver, subsequent hepatocellular carcinoma and terminal liver disease. HCV is the most prevalent cause of hepatocellular cancer and cause of patients requiring liver transplantations in the western world.
  • HIV human immunodeficiency virus
  • anti-HCV therapeutics There are considerable barriers to the development of anti-HCV therapeutics, which include, but are not limited to, the persistence of the virus, the genetic diversity of the virus during replication in the host, the high incident rate of the virus developing drug-resistant mutants, and the lack of reproducible infectious culture systems and small-animal models for HCV replication and pathogenesis. In a majority of cases, given the mild course of the infection and the complex biology of the liver, careful consideration must be given to antiviral drugs, which are likely to have significant side effects.
  • the present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds.
  • the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are useful as antiviral agents.
  • the present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
  • A is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
  • each Ri is independently selected from
  • optionally substituted alkyl optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
  • G is -E-R 5 ;
  • E is absent; optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; or -0-, -S-, -N(R 3 )-, -N(R 3 )S(O p )-, -N(R 3 )C(0)-, -N(R 3 )
  • each p is independently 0, 1, or 2;
  • R 5 is H; optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 3 and R4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen;
  • L is absent or is selected from optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
  • j 0, 1, 2, 3, or 4;
  • k 0, 1, 2, or 3;
  • n 0, 1, or 2;
  • Various compounds of the invention demonstrate substantially improved antiviral activity against HCV genotype 3a infections compared to unsubstituted phenanthridine compounds.
  • Various compounds of the invention also demonstrate substantially improved antiviral activity against clinically relevant resistant mutants, especially genotype la R155K and D169V. Such compounds also exhibit improved pharmacokinetic properties, as measured preclinically in animals such as rat or dog.
  • A is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
  • optionally substituted aryl optionally substituted arylalkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted carbocyclic;
  • each Ri is independently selected from
  • optionally substituted alkyl optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
  • G is -E-R 5 ;
  • E is absent; optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; or -0-, -S-, -N(R 3 )-, -N(R 3 )S(O p )-, -N(R 3 )C(0)-, -N(R 3 )
  • each p is independently 0, 1, or 2;
  • R 5 is H; optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 3 and R4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen; L is absent or is selected from optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
  • j 0, 1, 2, 3, or 4;
  • k 0, 1, 2, or 3;
  • n 0, 1, or 2;
  • n 1, 2, 3, or 4; and enotes a carbon-carbon single bond ( ) or double bond
  • the invention provides a compound of formula ⁇ :
  • J, A, Ri, G, R 5 , L, j, k, m, and n are as defined above.
  • E is -NHS(O)- or -NHS(0 2 )-
  • R5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, or imidazolyl, each of which is optionally substituted.
  • J is -C(O)- and A is optionally substituted -Ci-C 8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, optionally substituted -Ci-C 8 alkoxy, optionally substituted heteroaryl, optionally substituted -C 3 -C 12 cycloalkyl, or optionally substituted -C 3 -Ci 2 heterocycloalkyl.
  • each Ri is independently selected from halogen, hydroxy, amino, -CN, -CF 3 , -N 3 , -N0 2 , -OR 4 , -SR4, -SOI , -S0 2 R 4 , -N(R 3 )S(0 2 ) -R4, -N(R 3 )
  • optionally substituted carbocyclic or optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; wherein at least one Ri is halogen or -OR 4 .
  • each Ri is independently halogen, hydroxy, amino, -CN, -
  • Ri is halogen or and n is 1, 2 or 3.
  • the invention provides a compound of formula II,
  • A is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, optionally substituted arylalkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted carbocyclic;
  • each Ri is independently selected from
  • R5 is H; optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 3 and R4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted haloalkyl, optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen;
  • n 1, 2, 3, or 4; and enotes a carbon-carbon single bond ( ) or double bond
  • R5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, or imidazolyl, each of which is optionally substituted.
  • J is -C(O)- and A is optionally substituted -Ci-C 8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, optionally substituted -Ci-C 8 alkoxy, optionally substituted heteroaryl, optionally substituted -C 3 -C 12 cycloalkyl, or optionally substituted -C 3 -Ci 2 heterocycloalkyl.
  • the invention provides a
  • the invention provides a
  • E is -NH-, -NHS(0) p -, or -NH(C0)S(0) p -, and p is 2.
  • E is -NHS(0) p -, and p is 2.
  • R 5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, or imidazolyl, each of which is optionally substituted.
  • R5 is optionally substituted cyclopropyl.
  • J is -C(O)-.
  • n 1
  • A is optionally substituted -Ci-C 8 alkyl, containing 0, 1,
  • heteroatoms selected from O, S, or N optionally substituted -Ci-C 8 haloalkyl, optionally substituted -Ci-C 8 hydroxyalkyl, optionally substituted aryl, optionally substituted -Ci-C 8 alkoxy, optionally substituted heteroaryl, optionally substituted -C 12 cycloalkyl, or optionally substituted -Ci 2 heterocyclyl.
  • A is selected from Me, Et, Pr, i-Pr, Bu, s-Bu, t-Bu,
  • J' is -NHC(O)-, -NHC(0)0-, -C(O)-, -O-C(O)-, -C(S)-, -S(O)-, -S(0 2 )-;
  • A' is optionally substituted -Ci-C 8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted -Ci-C 8 haloalkyl, optionally substituted aryl, optionally substituted -Ci-C 8 alkoxy, optionally substituted heteroaryl, optionally substituted -C 3 -C12 cycloalkyl, or optionally substituted -C 3 -Ci 2 heterocyclyl;
  • R' is H, optionally substituted -Ci-C 8 alkyl, optionally substituted -C 3 -C 12 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted -C 3 -C 12 heterocyclyl;
  • R" is H, optionally substituted -Ci-C 8 alkyl, optionally substituted -C 3 -C 12 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted -C 3 -C 12 heterocyclyl;
  • t 0 or 1.
  • J' is -NHC(O)-, or -NHC(0)0-;
  • A' is optionally substituted -Ci-C 8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, or optionally substituted heteroaryl; R' is H, optionally substituted -Q-Q alkyl or optionally substituted -C 3 -C 12 cycloalkyl,
  • R" is H
  • t 0 or 1.
  • A' is Me, Et, Pr, i-Pr, Bu, s-Bu, t-Bu, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, imidazolyl,
  • R' is Et, Pr, i-Pr, t-Bu, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydropyran, CH 2 -i-Pr, CH 2 -t-Bu, CH 2 -cyclopropyl, CH 2 -cyclobutyl, CH 2 - cyclopentyl, CH 2 -cyclohexyl, or CH 2 -tetrahydropyran.
  • J" is -NC(O)- or -NC(0)0-; and A" is optionally substituted -Ci-Cs alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, or optionally substituted heteroaryl.
  • A" is t-Bu, optionally substituted pyrazine, or optionally substituted isoxazole.
  • A is -CHRz(OH)-, wherein Rz is cyclohexyl, i-Pr, i-Bu, t-Bu, or CF 3 .
  • A is CHF 2 -R Y , wherein R Y is Ph or Et.
  • E is -N(R 3 )S(0) p -; -
  • R5 is optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl.
  • R 5 is carbocyclic.
  • R5 is cyclopropyl, which is optionally substituted.
  • J is -C(O)-.
  • A is an optionally substituted alkyl, an optionally substituted haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl.
  • A is methyl, ethyl, propyl, iso- propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, heptyl,
  • each Ri is independently selected from H, halogen, hydroxy, amino, -CN, -CF 3 , -N 3 , -N0 2 , -OR 4 , -SR 4 , -NR 3 R 4 , optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; optionally substituted haloalkyl, or optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl; wherein at least one Ri is halogen or -OR 4 -.
  • each R 3 and R 4 is independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen.
  • G is E-R5, wherein E is - NHS(0)2- and R5 is cyclopropyl, which is optionally substituted.
  • A is optionally substituted cycloalkyl.
  • A is optionally substituted heterocyclyl. In another embodiment of each of the above-described aspects of the invention, A is optionally substituted alkyl.
  • A is optionally substituted heteroaryl.
  • J is - C(O)-; and A is optionally substituted cycloalkyl.
  • J is - C(O)-; and A is optionally substituted heterocyclyl.
  • J is - C(O)-; and A is optionally substituted alkyl.
  • each of the above-described aspects of the invention J is - C(O)-; and A is optionally substituted heteroaryl. In another embodiment of each of the above-described aspects of the invention J is
  • each of the above-described aspects of the invention J is C(O)-; and A is -CHR z (OH)- . In another embodiment of each of the above-described aspects of the invention J is - C(O)-; and A is CHF 2 -R Y .
  • E is NHS(0) 2 ;
  • R 5 is cyclopropyl or methyl-substituted cyclopropyl; and
  • A is optionally substituted cycloalkyl.
  • E is NHS(0) 2 ;
  • R 5 is cyclopropyl or methyl-substituted cyclopropyl; and A is optionally substituted heterocyclyl.
  • E is NHS(0) 2 ;
  • R 5 is cyclopropyl or methyl-substituted cyclopropyl; and A is optionally substituted alkyl.
  • E is NHS(0) 2 ;
  • R 5 is cyclopropyl or methyl-substituted cyclopropyl; and
  • A is optionally substituted heteroaryl.
  • R 5 is cyclopropyl or methyl-substituted cyclopropyl; and A is
  • E is NHS(0) 2 ;
  • R 5 is cyclopropyl or methyl-substituted cyclopropyl; and
  • A is -CHRz(OH)-.
  • E is NHS(0) 2 ; R 5 is cyclopropyl or methyl-substituted cyclopropyl; and A is CHF 2 -R Y .
  • E is NHS(0) 2 ; R 5 is cyclopropyl or methyl-substituted cyclopropyl; J is -C(O)-; and A is optionally substituted cycloalkyl.
  • E is NHS(0) 2 ;
  • R 5 is cyclopropyl or methyl-substituted cyclopropyl;
  • J is -C(O)-; and
  • A is optionally substituted heterocyclyl.
  • E is NHS(0) 2 ; R 5 is cyclopropyl or methyl-substituted cyclopropyl; J is -C(O)-; and A is optionally substituted alkyl.
  • E is -
  • R 5 is cyclopropyl or methyl-substituted cyclopropyl; J is -C(O)-; and A is optionally substituted heteroaryl.
  • E is - NHS(0) 2 ;
  • R 5 is cyclopropyl or methyl-substituted cyclopropyl;
  • J is -C(O)-; and
  • A is
  • E is NHS 0) 2 ;
  • R 5 is cyclopropyl or methyl-substituted cyclopropyl;
  • J is -C(O)-; and
  • A is
  • E is ⁇ NHS(0) 2 ;
  • R 5 is cyclopropyl or methyl-substituted cyclopropyl;
  • J is -C(O)-; and
  • A is - CHRz(OH)-.
  • E is ⁇ NHS(0) 2 ;
  • R 5 is cyclopropyl or methyl-substituted cyclopropyl;
  • J is -C(O)-; and
  • A is CHF 2 - RY.
  • the invention provides a compound of formula III:
  • A is optionally substituted alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, or optionally substituted heteroaryl;
  • each Ri is independently selected from halogen, hydroxy, -OR 4 , -C(0)-0-R4, -
  • Ri is halogen or -OR 4 ;
  • R x is H or optionally substituted alkyl
  • R 3 and R 4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted haloalkyl, optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen; and
  • n 1, 2, or 3.
  • the invention provides a compound as described above,
  • A is optionally substituted -Ci-C 8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from 0, S, or N; optionally substituted -Ci-C 8 haloalkyl, optionally substituted -Ci-C 8 hydroxyalkyl, optionally substituted aryl, optionally substituted -Ci-C 8 alkoxy, optionally substituted heteroaryl, optionally substituted -C 3 -C 12 cycloalkyl, or optionally substituted -C3-Ci 2 heterocyclyl.
  • A is , wherein:
  • J' is -NHC(O)-, or -NHC(0)0-;
  • A' is optionally substituted -Ci-C 8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, or optionally substituted heteroaryl;
  • R' is H, optionally substituted -Ci-C 8 alkyl or optionally substituted -C3-C12 cycloalkyl,
  • R" is H
  • t 0 or 1.
  • A' is Me, Et, Pr, i-Pr, Bu, s-Bu, t-Bu, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, imidazolyl,
  • R' is Et, Pr, i-Pr, t-Bu, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydropyran, CH 2 -i-Pr, CH 2 -t-Bu, CH 2 -cyclopropyl, CH 2 -cyclobutyl, CH 2 - cyclopentyl, CH 2 -cyclohexyl, or CH 2 -tetrahydropyran.
  • J is -NC(0)- or -NC(0)0-; and A" is optionally substituted -Ci-C 8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from 0, S, or N, or optionally substituted heteroaryl.
  • A" is t-Bu, optionally substituted pyrazine, or optionally substituted isoxazole.
  • A is -CHRz(OH)-, wherein Rz is cyclohexyl, i-Pr, i-Bu, t-Bu, or CF 3 .
  • A is CHF 2 -R Y , wherein R Y is Ph or Et.
  • A is optionally substituted cycloalkyl.
  • A is optionally substituted heterocyclyl. In another embodiment, A is optionally substituted alkyl. In another embodiment, A is optionally substituted heteroaryl.
  • A is wherein A' , J', R' R" and t are as defined previously, and
  • A is -CHR z (OH)-, wherein R z is cyclohexyl, i-Pr, i-Bu, t-Bu, or CF 3 ;
  • nM 0.1-0.5 la stable replicon
  • nM 0.1-0.5 lb stable replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM >1.0 3a transient replicon
  • nM 0.5-1.0 la stable replicon
  • nM 0.1-0.5 lb stable replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM 0.5-1.0 3a transient replicon
  • nM 0.5-1.0 lb stable replicon (nM) la transient replicon (nM) lb transient replicon (nM)
  • nM 0.1-0.5 lb stable replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM >1.0 3a transient replicon
  • nM 0.5-1.0 la stable replicon
  • nM 0.1-0.5 lb stable replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM >1.0 3a transient replicon
  • nM 0.5-1.0 la stable replicon
  • nM 0.1-0.5 lb stable replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM >1.0 3a transient replicon
  • nM 0.5-1.0 la stable replicon
  • nM 0.1-0.5 lb stable replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM ⁇ 1.0 3a transient replicon
  • nM 0.5-1.0 la stable replicon
  • nM 0.1-0.5 lb stable replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM ⁇ 1.0 3a transient replicon
  • nM 0.1-0.5 la stable replicon
  • nM 0.1-0.5 lb stable replicon
  • nM la transient replicon
  • nM lb transient replicon
  • n 3 c >1.0 3a transient replicon (nM)
  • nM 0.5-1.0 la stable replicon
  • nM 0.1-0.5 lb stable replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM >1.0 3a transient replicon
  • nM ⁇ 0.1 lb stable replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM 0.1-0.5 la stable replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM 0.5-1.0 la stable replicon
  • nM 0.1-0.5 lb stable replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM ⁇ 0.1 lb stable replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM 0.5-1.0 la stable replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.5-1.0 lb transient replicon
  • nM 0.1-0.5 la stable replicon
  • nM 0.1-0.5 lb stable replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.5-1.0 lb transient replicon
  • nM 0.5-1.0 3a transient replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM 0.1-0.5 3a transient replicon
  • nM ⁇ 0.1 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) 0.1-0.5 3a transient replicon (nM)
  • nM ⁇ 0.1 lb stable replicon
  • nM ⁇ 0.1 la transient replicon
  • nM ⁇ 0.1 lb transient replicon
  • nM 0.1-0.5 3a transient replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM 0.1-0.5 3a transient replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM 0.1 3a transient replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM 0.1-0.5 3a transient replicon
  • nM 0.5-1.0 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) 0.1-0.5 3a transient replicon (nM)
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM 0.1-0.5 3a transient replicon
  • nM 0.1-0.5 la transient replicon
  • nM 0.1-0.5 lb transient replicon
  • nM 0.5-1.0 3a transient replicon
  • Each compound's anti-HCV activity can be determined by measuring the activity of the luciferase reporter gene in the replicon in the presence of 5% FBS.
  • the luciferase reporter gene, and selectable marker gene for replicons stably maintained in cell lines, is placed under the translational control of the poliovirus IRES instead of the HCV IRES, and HuH-7 cells are used to support the replication of the replicon.
  • the inhibitory activities of the compounds of the present invention can be evaluated using a variety of assays known in the art.
  • stable subgenomic replicon cell lines can be used for compound characterization in cell culture, including those derived from genotypes la-H77, lb-N and lb-Conl, obtained from University of Texas Medical Branch, Galveston, TX (la-H77 and lb-N) or Apath, LLC, St. Louis, MO (lb-Conl).
  • Chimeric replicons using the genotype la or lb replicons with insertion of NS3 genes from isolates from humans infected with genotypes la or lb can be used to measure inhitory activity against a panel of the target protein from natural isolates.
  • Chimeric replicons using the genotype la or lb replicons with insertion of NS3 genes from isolates from humans infected with genotypes 3a, 4 or 6 can be used to measure inhitory activity against representatives of those genotypes.
  • the genotype la replicon construct contains the NS3-NS5B coding region derived from the H77 strain of HCV (la-H77).
  • the replicon also has a firefly luciferase reporter and a neomycin phosphotransferase (Neo) selectable marker.
  • These two coding regions comprise the first cistron of the bicistronic replicon construct, with the second cistron containing the NS3-NS5B coding region with addition of adaptive mutations E1202G, K1691R, K2040R and S2204I.
  • the lb-Conl and lb-N replicon constructs are identical to the la-H77 replicon, except that the HCV 5' UTR, 3' UTR, and NS3-NS5B coding region are derived from the lb-Conl or lb-N strain, and the adaptive mutations are K1609E, K1846T and Y3005C for lb-Conl or A1098T, E1202G, and S2204I for lb-N.
  • the lb-Conl replicon construct contains a poliovirus IRES between the HCV IRES and the luciferase gene.
  • Replicon cell lines can be maintained in Dulbecco's modified Eagles medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS), 100 IU/ml penicillin, 100 mg/ml streptomycin (Invitrogen), and 200 mg/ml G418 (Invitrogen).
  • DMEM Dulbecco's modified Eagles medium
  • FBS fetal bovine serum
  • penicillin 100 IU/ml bovine serum
  • streptomycin Invitrogen
  • G418 Invitrogen
  • the inhibitory effects of the compounds of the invention on HCV replication can also be determined by measuring activity of the luciferase reporter gene encoded by subgenomic replicons not containing the Neo selectable marker, that are transiently expressed in cells.
  • the adaptive mutations encoded by the la-H77, lb-N and lb-Con-1 replicons are the same as listed above.
  • the lb-Conl replicon used for these transient assays contains the NS2-NS5B coding region rather than the NS3-5B coding region.
  • These replicons may encode target NS3 genes as described for stable subgenomic replicons or they may encode amino acid variants that confer varying degrees of susceptibility to the drug.
  • variants could include R155K, D168E or D168V in a genotype la NS3 gene; R155K, A156T or D168V in a genotype lb NS3 gene; S138T, A166T or Q168R in a genotype 3a NS3 gene.
  • cells can be transfected with the replicon by electroporation and seeded into 96 well plates at a density of 5000 cells per well in 100 ⁇ DMEM containing 5% FBS.
  • concentration and the EC 50 value can be calculated using nonlinear regression curve fitting to the 4-parameter logistic equation and GraphPad Prism 4 software.
  • representative compounds of the present invention showed significantly inhibitory activities against HCV replication.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound provided herein (e.g. formula I), or a pharmaceutically acceptable salt, ester, or prodrug thereof, in combination with a compound provided herein (e.g. formula I), or a pharmaceutically acceptable salt, ester, or prodrug thereof, in combination with a compound provided herein (e.g. formula I), or a pharmaceutically acceptable salt, ester, or prodrug thereof, in combination with a
  • the pharmaceutical compositions of the present invention may further contain one or more other anti-HCV agents.
  • anti-HCV agents include, but are not limited to, oc-interferon; ⁇ -interferon; pegylated interferon-oc; pegylated interferon-lambda; ribavirin; viramidine; R-5158; nitazoxanide; amantadine;
  • HCV polymerase inhibitors such as R7128, R1626, R4048, T-1106, PSI-7851, PF-00868554, ANA-598, IDX184, IDX102, IDX375, GS-9190, VCH-759, VCH- 916, MK-3281, BCX-4678, MK-3281, VBY708, ANA598, GL59728 or GL60667; BMS- 790052; BMS-791325; BMS-650032; HCV entry, helicase or internal ribosome entry site inhibitors; or other HCV replication inhibitors such as GS-9132, ACH-1095, AP-H005, A- 831, A-689, AZD2836.
  • HCV polymerase inhibitors such as R7128, R1626, R4048, T-1106, PSI-7851, PF-00868554, ANA-598, IDX184, IDX102, IDX375, GS-9190, VCH-759
  • compositions of the present invention may further contain another HCV protease inhibitor, such as telaprevir, boceprevir, ITMN-191, BI-201335, TMC-435, MK-7009, VBY-376, VX-500, VX-813, PHX-B, ACH-1625, IDX136, or IDX316.
  • another HCV protease inhibitor such as telaprevir, boceprevir, ITMN-191, BI-201335, TMC-435, MK-7009, VBY-376, VX-500, VX-813, PHX-B, ACH-1625, IDX136, or IDX316.
  • the invention provides a pharmaceutical composition further comprising pegylated interferon, another anti- viral, anti-bacterial, anti-fungal or anti-cancer agent, or an immune modulator, and/or further comprising a cytochrome P450
  • the cytochrome P450 monooxygenase inhibitor is ritonavir.
  • the invention provides for the use of a compound of the invention to manufacture an agent for preventing or treating viral infection.
  • the invention provides for the use of a compound of the invention to manufacture an agent for preventing or treating hepatitis C infection.
  • the present invention also contemplates the use of a solvate (e.g., hydrate) of a compound of the invention to manufacture pharmaceutical compositions for preventing or treating hepatitis C infection.
  • solvate refers to the physical association of a compound of the invention with one or more solvent molecule, whether organic or inorganic. This physical association often includes hydrogen bonding.
  • the solvate is capable of isolation, for example, when one or more solvate molecules are incorporated in the crystal lattice of the crystalline solid.
  • the compounds or pharmaceutical compositions of the invention are administered with ritonavir, either simultaneously or sequentially.
  • a compound or a pharmaceutical composition of the invention is administered in the same composition as ritonavir.
  • a compound or a a pharmaceutical composition of the invention is administered in the same composition as ritonavir.
  • composition thereof of the invention is administered in a different manner
  • composition than ritonavir composition than ritonavir.
  • compositions of the present invention may further comprise inhibitor(s) of other targets in the HCV life cycle, including, but not limited to, helicase, polymerase, metalloprotease, CD81, NS5A, cyclophilin, and internal ribosome entry site (IRES).
  • inhibitor(s) of other targets in the HCV life cycle including, but not limited to, helicase, polymerase, metalloprotease, CD81, NS5A, cyclophilin, and internal ribosome entry site (IRES).
  • the invention provides a method of treating a viral infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of the invention described herein (e.g. formula I), or a pharmaceutically acceptable salt, ester or prodrug thereof, or a pharmaceutical composition comprising the same.
  • a compound of the invention described herein e.g. formula I
  • a pharmaceutically acceptable salt, ester or prodrug thereof e.g. formula I
  • the present invention includes methods of treating hepatitis C infections in a subject in need of such treatment by administering to said subject an anti-HCV virally effective amount or an inhibitory amount of the compounds or pharmaceutical compositions of the present invention.
  • the present invention includes methods of treating hepatitis C infections in a subject in need of such treatment by administering to said subject a compound or a pharmaceutical composition of the present invention.
  • the methods can further include administration of an additional therapeutic agent, including another antiviral agent or an anti-HCV agent as described hereinabove.
  • the additional agent can be co-administered (such as concurrently administered or sequentially administered) with a compound (a pharmaceutically acceptable salt, ester or prodrug thereof) or a pharmaceutical composition of the present invention.
  • the additional agent(s) and a compound (or a pharmaceutically acceptable salt, ester or prodrug thereof) of the present invention can be formulated in the same composition, or in different compositions but co-administered concurrently or sequentially.
  • the methods herein can further include the step of identifying that the subject is in need of treatment for hepatitis C infection.
  • the identification can be by subjective (e.g., health care provider determination) or objective (e.g., diagnostic test) means.
  • the invention provides a method of inhibiting the replication of hepatitis C virus, the method comprising contacting a hepatitis C virus with an effective amount of a compound or pharmaceutical composition of the invention.
  • the invention provides a method as described above, further comprising administering an additional anti-hepatitis C virus agent.
  • anti- hepatitis C virus agents include, but are not limited to, oc-interferon; ⁇ -interferon; pegylated interferon-oc; pegylated interferon-lambda; ribavirin; viramidine; R-5158; nitazoxanide;
  • HCV polymerase inhibitors such as R7128, R1626, R4048, T-1106, PSI-7851, PF-00868554, ANA-598, IDX184, IDX102, IDX375, GS-9190, VCH-759, VCH-916, MK-3281, BCX-4678, MK-3281, VBY708, ANA598, GL59728 or GL60667; BMS-790052; BMS-791325; BMS-650032; HCV entry, helicase or internal ribosome entry site inhibitors; or other HCV replication inhibitors such as GS-9132, ACH- 1095, AP-H005, A-831, A-689, AZD2836.
  • HCV polymerase inhibitors such as R7128, R1626, R4048, T-1106, PSI-7851, PF-00868554, ANA-598, IDX184, IDX102, IDX375, GS-9190, VCH-759, V
  • a compound or a pharmaceutical composition of the present invention is coadministered with, or used in combination with, pegylated interferon (e.g., pegylated interferon alpha-2a or 2b) and ribavirin.
  • pegylated interferon e.g., pegylated interferon alpha-2a or 2b
  • ribavirin e.g., ribavirin.
  • HCV genotype- 1 e.g., genotype la or lb
  • HCV genotype- 2 e.g., genotype la or lb
  • other HCV genotypes such as genotypes 2, 3, 4, 5 or 6, can also be treated with a compound or a pharmaceutical composition of the present invention.
  • the invention provides a method as described above, further comprising administering another HCV protease inhibitor, an HCV polymerase inhibitor, an HCV helicase inhibitor, or an internal ribosome entry site (IRES)inhibitor, such as telaprevir, boceprevir, ITMN-191, BI-201335, TMC-435, MK-7009, VBY-376, VX-500, VX-813, PHX-B, ACH-1625, IDX136, IDX316, pegylated interferon, another anti-viral, anti- bacterial, anti-fungal or anti-cancer agent, or an immune modulator, and/or further comprising a cytochrome P450 monooxygenase inhibitor or a pharmaceutically acceptable salt thereof.
  • the cytochrome P450 monooxygenase inhibitor is ritonavir.
  • An additional embodiment of the present invention includes methods of treating biological samples by contacting the biological samples with the compounds of the present invention.
  • Yet another aspect of the present invention is a process of making any of the compounds delineated herein employing any of the synthetic means delineated herein.
  • halo indicates that the substituent to which the prefix is attached is substituted with one or more independently selected halogen radicals. For example,
  • haloalkyl means an alkyl substituent wherein at least one hydrogen radical is replaced with a halogen radical.
  • a linking element in a depicted structure is "absent", then the left element in the depicted structure is directly linked to the right element in the depicted structure.
  • a chemical structure is depicted as X-L-Y wherein L is absent, then the chemical structure is X-Y.
  • alkyl refers to a saturated, straight- or branched-chain hydrocarbon radical typically containing from 1 to 20 carbon atoms.
  • β€œCi-C 8 alkyl” contains from one to eight carbon atoms.
  • alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, w-butyl, tert-butyl, neopentyl, n-hexyl, heptyl, octyl radicals and the like.
  • alkenyl denotes a straight- or branched-chain hydrocarbon radical containing one or more double bonds and typically from 2 to 20 carbon atoms.
  • C 2 -C8 alkenyl contains from two to eight carbon atoms.
  • Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, l-methyl-2-buten-l-yl, heptenyl, octenyl and the like.
  • alkynyl denotes a straight- or branched-chain hydrocarbon radical containing one or more triple bonds and typically from 2 to 20 carbon atoms.
  • C 2 -C 8 alkynyl contains from two to eight carbon atoms.
  • Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl and the like.
  • alkylene refers to a divalent group derived from a straight or branched saturated hydrocarbyl chain typically containing from 1 to 20 carbon atoms, more typically from 1 to 8 carbon atoms.
  • Representative examples of alkylene include, but are not limited to, -CH 2 -, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, and -CH 2 CH(CH 3 )CH 2 -.
  • alkenylene refers to a divalent unsaturated hydrocarbyl group which may be linear or branched and which has at least one carbon-carbon double bond.
  • An alkenylene group typically contains 2 to 20 carbon atoms, more typically from 2 to 8 carbon atoms.
  • alkynylene refers to a divalent unsaturated hydrocarbon group which may be linear or branched and which has at least one carbon-carbon triple bond.
  • Representative alkynylene groups include, by way of example, -C ⁇ C-, -C ⁇ C-CH 2 -, -C ⁇ C-CH 2 -CH 2 -, -CH 2 - C ⁇ C-CH 2 -, -C ⁇ C-CH(CH 3 )-, and -CH 2 -C ⁇ C-CH(CH 2 CH 3 )-.
  • cycloalkyl refers to a) a monovalent group derived from a monocyclic or polycyclic saturated carbocyclic ring compound; or b) a saturated, partially saturated or completely unsaturated ring system containing zero heteroatom ring atom and typically from 3 to 18 carbon ring atoms.
  • a carbocyclyl may be, without limitation, a single ring, or two or more fused rings, or bridged or spiro rings.
  • a carbocyclyl may contain, for example, from 3 to 14 ring members, from 3 to 10 ring members, from 3 to 8 ring members, or from 3 to 6 ring members.
  • a substituted carbocyclyl may have either cis or trans geometry.
  • Representative examples of carbocyclyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl cyclopropyl, cycloheptyl, cyclooctyl,
  • cyclopentenyl cyclopentadienyl, cyclohexadienyl, adamantyl, decahydro-naphthalenyl, octahydro-indenyl, cyclohexenyl, phenyl, naphthyl, fluorenyl, indanyl, 1,2,3,4-tetrahydro- naphthyl, indenyl, isoindenyl, bicyclodecanyl, anthracenyl, phenanthrene, benzonaphthenyl (also known as "phenalenyl”), decalinyl, and norpinanyl and the like.
  • a carbocyclyl group can be attached to the parent molecular moiety through any substitutable carbon atom of the group.
  • aryl refers to an aromatic carbocyclyl containing from 6 to 14 carbon ring atoms. Non-limiting examples of aryls include phenyl, naphthalenyl, anthracenyl, and indenyl and the like.
  • An aryl group can be connected to the parent molecular moiety through any substitutable carbon atom of the group.
  • aralkyl or "arylalkyl” refers to an alkyl residue attached to an aryl ring.
  • aralkyl examples include, but are not limited to, benzyl, phenethyl and the like.
  • heteroaryl means an aromatic heterocyclyl typically containing from 5 to 18 ring atoms.
  • a heteroaryl may be a single ring, or two or more fused rings.
  • five-membered heteroaryls include imidazolyl; furanyl; thiophenyl (or thienyl or thiofuranyl); pyrazolyl; oxazolyl; isoxazolyl; thiazolyl; 1,2,3-, 1,2,4-, 1,2,5-, and
  • Non-limiting examples of six-membered heteroaryls include pyridinyl; pyrazinyl; pyrimidinyl; pyridazinyl; and 1,3,5-, 1,2,4-, and 1,2,3-triazinyl.
  • Non-limiting examples of 6/5-membered fused ring heteroaryls include benzothiofuranyl, isobenzothiofuranyl, benzisoxazolyl, benzoxazolyl, purinyl, and anthranilyl.
  • Non-limiting examples of 6/6-membered fused ring heteroaryls include quinolinyl; isoquinolinyl; and benzoxazinyl (including cinnolinyl and quinazolinyl).
  • heteroarylkyl refers to an alkyl residue attached to a heteroaryl ring. Examples include, but are not limited to, pyridinylmethyl, pyrimidinylethyl and the like.
  • heterocycloalkyl refers to a non-aromatic 3-, 4-, 5-, 6- or 7-membered ring or a bi- or tri-cyclic group fused system, where (i) each ring contains between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, (ii) each 5-membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (iii) the nitrogen and sulfur heteroatoms may optionally be oxidized, (iv) the nitrogen heteroatom may optionally be quaternized, and (iv) any of the above rings may be fused to a benzene ring.
  • heterocycloalkyl groups include, but are not limited to, [l,3]dioxolane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl and the like.
  • heterocyclic or β€œheterocyclo” or β€œheterocyclyl” refer to a saturated (e.g.,
  • heterocycloalkyl e.g., β€œheterocycloalkenyl” or
  • heterocycloalkynyl or completely unsaturated (e.g., "heteroaryl”) ring system typically containing from 3 to 18 ring atoms, where at least one of the ring atoms is a heteroatom (i.e., nitrogen, oxygen or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, nitrogen, oxygen and sulfur.
  • a heterocyclyl group can be linked to the parent molecular moiety via any substitutable carbon or nitrogen atom in the group, provided that a stable molecule results.
  • a heterocyclyl may be, without limitation, a single ring, which typically contains from 3 to 14 ring atoms, from 3 to 8 ring atoms, from 3 to 6 ring atoms, or from 5 to 6 ring atoms.
  • heterocyclyls include furanyl, dihydrofuranyl, pyrrolyl, isopyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, isoimidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, triazolyl, tetrazolyl, dithiolyl, oxathiolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, thiodiazolyl, oxathiazolyl, oxadiazoly, pyranyl, dihydropyranyl, pyridinyl, piperidinyl, pyridazinyl, pyrimidinyl, pyrazin
  • a heterocyclyl may also include, without limitation, two or more rings fused together, such as, for example, naphthyridinyl, thiazolpyrimidinyl, thienopyrimidinyl, pyrimidopyrimidinyl, or
  • a heterocyclyl may comprise one or more sulfur atoms as ring members; and in some cases, the sulfur atom(s) is oxidized to SO or S0 2 .
  • the nitrogen heteroatom(s) in a heterocyclyl may or may not be quaternized, and may or may not be oxidized to N-oxide. In addition, the nitrogen heteroatom(s) may or may not be N-protected.
  • optionally substituted refers to groups that are substituted or unsubstituted by independent replacement of one, two, or three or more of the hydrogen atoms thereon with substituents including, but not limited to:
  • -NH 2 protected amino, -NH alkyl, -NH alkenyl, -NH alkynyl, -NH cycloalkyl, -NH - aryl, -NH -heteroaryl, -NH -heterocyclic, -dialkylamino, -diarylamino, -diheteroarylamino,
  • -O- alkyl -O- alkenyl, -O- alkynyl, -O- cycloalkyl, -O-aryl, -O-heteroaryl, -O- heterocyclic, -C(O)- alkyl, -C(O)- alkenyl, -C(O)- alkynyl, -C(O)- cycloalkyl, -C(0)-aryl, -C(O)- heteroaryl, -C(0)-heterocycloalkyl,
  • -S(O)- alkyl - S(O)- alkenyl, - S(O)- alkynyl, - S(O)- cycloalkyl, - S(0)-aryl, - S(O)- heteroaryl, - S(0)-heterocycloalkyl -S0 2 NH 2 , -S0 2 NH- alkyl, -S0 2 NH- alkenyl, -S0 2 NH- alkynyl, -S0 2 NH- cycloalkyl, -S0 2 NH- aryl, -S0 2 NH- heteroaryl, -S0 2 NH- heterocycloalkyl,
  • -alkyl -alkenyl, -alkynyl, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, - heterocycloalkyl, -cycloalkyl, -carbocyclic, -heterocyclic, polyalkoxyalkyl, polyalkoxy, - methoxymethoxy, -methoxyethoxy, -SH, -S- alkyl, -S- alkenyl, -S- alkynyl, -S- cycloalkyl, - S-aryl, -S-heteroaryl, -S-heterocycloalkyl, or methylthiomethyl.
  • aryls, heteroaryls, carbocyclics, heterocyclics, alkyls, and the like can be further substituted.
  • halo and halogen refer to an atom selected from fluorine, chlorine, bromine and iodine.
  • subject refers to a mammal.
  • a subject therefore refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, and the like.
  • the subject is a human.
  • the subject may be either a patient or a healthy human.
  • hydroxy activating group refers to a labile chemical moiety which is known in the art to activate a hydroxy group so that it will depart during synthetic procedures such as in a substitution or elimination reactions.
  • hydroxy activating group include, but not limited to, mesylate, tosylate, triflate, p-nitrobenzoate, phosphonate and the like.
  • LG refers to any group that leaves in the course of a chemical reaction involving the group and includes but is not limited to halogen, brosylate, mesylate, tosylate, triflate, p-nitrobenzoate, phosphonate groups, for example.
  • protected hydroxy refers to a hydroxy group protected with a hydroxy protecting group, as defined above, including benzoyl, acetyl, trimethylsilyl, triethylsilyl, methoxymethyl groups, for example.
  • hydroxy protecting group refers to a labile chemical moiety which is known in the art to protect a hydroxy group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the hydroxy protecting group as described herein may be selectively removed. Hydroxy protecting groups as known in the are described generally in T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999).
  • hydroxy protecting groups include benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4- bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, methoxycarbonyl, tert- butoxycarbonyl, isopropoxycarbonyl, diphenylmethoxycarbonyl, 2,2,2- trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, 2-furfuryloxycarbonyl, allyloxycarbonyl, acetyl, formyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, t-butyl, 2,2,2-trichloroethyl, 2-trimethylsilyl ethyl, l,l-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, para-methoxybenzyl
  • hydroxy protecting groups for the present invention are acetyl (Ac or - C(0)CH 3 ), benzoyl (Bz or -C(0)C 6 H 5 ), and trimethylsilyl (TMS or -Si(CH 3 ) 3 ).
  • amino protecting group refers to a labile chemical moiety which is known in the art to protect an amino group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the amino protecting group as described herein may be selectively removed.
  • Amino protecting groups as known in the are described generally in T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of amino protecting groups include, but are not limited to, t-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, and the like.
  • protected amino refers to an amino group protected with an amino protecting group as defined above.
  • alkylamino refers to a group having the structure -N(R a Rb), where R a and R b are independent H or alkyl.
  • acyl includes residues derived from acids, including but not limited to carboxylic acids, carbamic acids, carbonic acids, sulfonic acids, and phosphorous acids. Examples include aliphatic carbonyls, aromatic carbonyls, aliphatic sulfonyls, aromatic sulfinyls, aliphatic sulfinyls, aromatic phosphates and aliphatic phosphates. Examples of aliphatic carbonyls include, but are not limited to, acetyl, propionyl, 2-fluoroacetyl, butyryl, 2-hydroxy acetyl, and the like.
  • the term "pharmaceutically acceptable salt” refers to those salts of the compounds formed by the process of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are
  • salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977).
  • the salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid.
  • Examples of pharmaceutically acceptable salts include, but are not limited to, nontoxic acid addition salts, or salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • Other pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate,
  • cyclopentanepropionate digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate,
  • alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, or magnesium salts, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.
  • ester refers to esters of the compounds formed by the process of the present invention which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
  • Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms.
  • esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.
  • prodrugs refers to those prodrugs of the compounds formed by the process of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like,
  • Prodrug means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to afford any compound delineated by the formulae of the instant invention.
  • Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al. (ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al., (ed).
  • This invention also encompasses pharmaceutical compositions containing, and methods of treating viral infections through administering, pharmaceutically acceptable prodrugs of compounds of the invention.
  • compounds of the invention having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs.
  • Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the invention.
  • the amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxyysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma- aminobutyric acid, citrulline, homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxyl groups can be derivatized as amides or alkyl esters.
  • Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxy carbonyls, as outlined in Advanced Drug Delivery Reviews, 1996, 19, 1 15.
  • Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups.
  • prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds.
  • stable refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject).
  • compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers.
  • pharmaceutically acceptable carrier means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, or as an oral or nasal spray.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water, alcohol or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, polysorbate, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), mono- or di- glycerides, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art such
  • a compound of the present invention can be dissolved in a pharmaceutically acceptable carrier containing, for example, one or more solubilizating agents (e.g., polysorbate 80 and mono and diglycerides), and other suitable excipients (e.g., an antioxidants such as ascorbyl palmitate, or a sweetening or flavoring agent).
  • solubilizating agents e.g., polysorbate 80 and mono and diglycerides
  • other suitable excipients e.g., an antioxidants such as ascorbyl palmitate, or a sweetening or flavoring agent.
  • sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S. P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the active compounds can also be in micro-encapsulated form with one or more excipients as noted above
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound to the body.
  • dosage forms can be made by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin.
  • the rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • viral infections are treated or prevented in a subject, such as a human or another animal, by administering to the subject a therapeutically effective amount of a compound of the invention (or a
  • terapΓ©uticaally effective amount of a compound of the invention, as used herein, means a sufficient amount of the compound so as to decrease the viral load in a subject and/or decrease the subject's HCV symptoms. As is well understood in the medical arts a therapeutically effective amount of a compound of this invention will be at a reasonable benefit/risk ratio applicable to any medical treatment.
  • An inhibitory amount or dose of the compounds of the present invention may range from about 0.1 mg/Kg to about 500 mg/Kg, alternatively from about 1 to about 50 mg/Kg. Inhibitory amounts or doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents.
  • viral infections are treated or prevented in a subject such as a human or lower mammal by administering to the subject an anti-hepatitis C virally effective amount or an inhibitory amount of a compound of the present invention, in such amounts and for such time as is necessary to achieve the desired result.
  • An additional method of the present invention is the treatment of biological samples with an inhibitory amount of a compound of composition of the present invention in such amounts and for such time as is necessary to achieve the desired result.
  • anti-hepatitis C virally effective amount of a compound of the invention, as used herein, means a sufficient amount of the compound so as to decrease the viral load in a biological sample or in a subject.
  • an anti-hepatitis C virally effective amount of a compound of this invention will be at a reasonable benefit/risk ratio applicable to any medical treatment.
  • inhibitory amount of a compound of the present invention means a sufficient amount to decrease the hepatitis C viral load in a biological sample or a subject. It is understood that when said inhibitory amount of a compound of the present invention is administered to a subject it will be at a reasonable benefit/risk ratio applicable to any medical treatment as determined by a physician.
  • biological sample(s), means a substance of biological origin intended for administration to a subject. Examples of biological samples include, but are not limited to, blood and components thereof such as plasma, platelets, subpopulations of blood cells and the like; organs such as kidney, liver, heart, lung, and the like; sperm and ova; bone marrow and components thereof; or stem cells.
  • another embodiment of the present invention is a method of treating a biological sample by contacting said biological sample with an inhibitory amount of a compound or pharmaceutical composition of the present invention.
  • a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary.
  • the dosage or frequency of administration, or both may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease.
  • the subject may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific inhibitory dose for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
  • the total daily inhibitory dose of the compounds of this invention administered to a subject in single or in divided doses can be in amounts, for example, from 0.01 to 50 mg/kg body weight or more usually from 0.1 to 25 mg/kg body weight.
  • Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose.
  • treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the
  • the treatment regimen comprises administration to a patient in need of such treatment from about 25 mg to about 6000 mg of a compound(s) of this invention per day in single or multiple doses, either with or without a cytochrome P450 monooxygenase inhibitor such as ritonavir.
  • the suitable daily dose for the co-administered cytochrome P450 monooxygenase inhibitor can range, without limitation, from 10 to 200 mg.
  • a compound(s) of the present invention is administered once daily or twice daily to achieve the desired daily dose amount.
  • a compound of the present invention can be administered to a patient twice a day with a total daily dose of 4000, 4200, 4400, 4600, 4800 or 5000 mg.
  • a compound of the present invention can be administered to a patient once or twice a day with a total daily dose of 200, 400, 600 or 800 mg, where the amount of ritonavir can be 25, 50 or 100 mg per administration.
  • A is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
  • optionally substituted aryl optionally substituted arylalkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted carbocyclic;
  • G is -E-R 5 ;
  • E is absent; optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; or -0-, -S-, -N(R 3 )-, -N(R 3 )S(O p )-, -N(R 3 )C(0)-, -N(R 3 )
  • each p is independently 0, 1, or 2;
  • R5 is H; optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 3 and R4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen;
  • L is absent or is selected from optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
  • j 0, 1, 2, 3, or 4;
  • k 0, 1, 2, or 3;
  • LG is a leaving group
  • each Ri is independently selected from
  • optionally substituted alkyl optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
  • n 1, 2, 3, or 4;
  • the compounds described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- , or as (D)- or (L)- for amino acids.
  • the present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms.
  • Optical isomers may be prepared from their respective optically active precursors by the procedures described above, or by resolving the racemic mixtures. The resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known to those skilled in the art.
  • the synthesized compounds can be separated from a reaction mixture and further purified by a method such as column chromatography, high pressure liquid chromatography, or recrystallization.
  • a method such as column chromatography, high pressure liquid chromatography, or recrystallization.
  • further methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art.
  • the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds.
  • the solvents, temperatures, reaction durations, etc. delineated herein are for purposes of illustration only and one of ordinary skill in the art will recognize that variation of the reaction conditions can produce the desired bridged macrocyclic products of the present invention.
  • Synthetic chemistry transformations and protecting group methodologies protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH
  • the compounds of this invention may be modified by appending various
  • the reaction mixture was cooled to room temperature and partitioned between ethyl acetate and 2 N HC1.
  • the organic phase was washed with water and then saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, and evaporated.
  • the resulting solid was purified by flash chromatography on silica gel, eluting with acetone/hexane, to provide the title compound (1.3 g, 60% yield).
  • Example lc 1.3g, 1.9 mmol
  • 1 N HCl 4.7 ml, 19 mmol
  • the reaction mixture was diluted with chloroform and toluene and evaporated to provide the title compound (1.11 g, quantitative yield) as a colorless solid. This material was used without further purification.
  • the reaction mixture was heated at 40 Β°C for 4 h.
  • the mixture was cooled to rt and partitioned between 2 N HC1 and dichloromethane.
  • the organic layer was concentrated under reduced pressure and then azeoptroped with toluene and chloroform to provide the title compound (0.812 g, quantitative yield) as a colorless solid that was used without further purification.
  • reaction mixture was cooled to room temperature and concentrated under reduced pressure to remove all tetrahydrofuran and methanol.
  • the mixture was diluted with 2 N HCl and the resulting solid was collected by filtration and dried on high vacuum overnight to provide the title compound (0.73 g, 85% yield) as a white solid. This material was taken forward without additional purification.
  • Carbonyl diimidazole (1.91 g, 11.8 mmol) was added and the reaction mixture was heated to 40 Β°C for 2 h. The reaction mixture was cooled to room temperature and 1-methylcyclopropane-l- sulfonamide (1.60 g, 11.8 mmol) was added. DBU (2.07 g, 13.6 mmol) was then added and the reaction mixture was stirred at room temperature for 16 h. The reaction mixture was filtered through Celite and rinsed with ethyl acetate, and the filtrate was washed with 1 N HC1. The resulting organic phase was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, filtered, and evaporated under reduced pressure.
  • Example 1 (Route 2). N-((2R,6S,13aS,14aR,16aS,Z)-2-(3-fluorophenanthridin-6-yloxy)-14a- (l-methylcyclopropylsulfonylcarbamoyl)-5,16-dioxo- 1,2,3,5, 6,7, 8,9, 10,11, 13a,14,14a,15, 16, 16a-hexadecahydrocyclopropa[e]pyrrolo[l, 2- a][l,4]diazacyclopentadecin-6-yl)-5-methylisoxazole-3-carboxamide
  • Example 2a 8-fluorophenanthridin-6-ol.
  • Example 2a To a mixture of 8-fluorophenanthridin-6-ol (Example 2a, 0.15 g, 0.69 mmol) in phosphorus oxychloride (1.06 g, 0.65 mL, 6.9 mmol) was added dimethylformamide (5 mg, 5 ⁇ ), and the reaction mixture was warmed to 80 Β°C and stirred under nitrogen for 3 h. The reaction mixture was cooled to room temperature and evaporated under reduced pressure. The residue was triturated with hexane, and the resulting solid isolated by vacuum filtration, washed with water, and dried to provide the title compound (0.15 g, 95% yield) which was used without additional purification.
  • Example 2d To a mixture of 8-fluorophenanthridin-6-ol (Exa, 0.15 g, 0.69 mmol) in phosphorus oxychloride (1.06 g, 0.65 mL, 6.9 mmol) was added dimethylformamide (5 mg, 5 ⁇ ), and the
  • reaction mixture was added dropwise to 2N HCl (200 mL) and the resulting solid was collected by vacuum filtration, rinsed with water, and dried.
  • the solid was purified by flash chromatography on silica gel, eluting with acetone/hexane, to provide the title compound (0.355 g, 70% yield) as a white solid.
  • Example 2 The title compound was prepared according to the procedure utilized for the preparation of Example 1, route 2, replacing the product of Example li with the product of Example 2e.
  • the product was purified by flash chromatography on silica gel eluting with a gradient of acetone/hexane to provide the title compound (17.5 mg, 50% yield) as a white solid.
  • the dipeptide 42c (1.91g) was dissolved in 15 mL of dioxane and 15 mL of 1 N LiOH aqueous solution and the hydrolysis reaction was carried out at room temperature for 4 hours.
  • the reaction mixture was acidified by 5% citric acid and extracted with 100 mL
  • H 2 The activity of recombinant HCV NS3 proteases derived from isolates representing genotypes 1, 2, 3 or 4 is measured by cleavage of the following peptide substrate: H 2
  • the substrate is labeled with a fluor and a fluorescence quencher. Cleavage results in release of the quencher and an increase in fluorescence.
  • NS3 protease is incubated with a dilution series of inhibitor in 150 mM NaCl, 10% Glycerol, 5 mM DTT, with or without 0.01% dodecyl maltoside for either 30 minutes or 300 minutes. Substrate is added at a concentration of 5 uM to initiate the reaction, and fluorescence is measured at 2 minute intervals for 30 minutes. Enzyme concentrations range from 10 to 100 nM in the absence of detergent, or 10-fold lower in the presence of detergent.
  • Substrate peptides are labeled with either EDANS and DABCYL (excitation 355 nm, emission 485 nm) or TAMRA and QSY (excitation 544 nm, emission 590 nm).
  • EDANS and DABCYL excitation 355 nm, emission 485 nm
  • TAMRA and QSY excitation 544 nm, emission 590 nm.
  • 3-fold serial dilutions starting with initial concentrations of 100 ⁇ , 200 ⁇ , or 2 mM are used.
  • Kj values approaching or lower than the enzyme concentration a tight-binding calculation format is used, with 24 dilutions of inhibitor covering a range of 0 to 100 nM inhibitor.
  • K values are calculated using the tight binding assay format, according to the following equation:
  • genotype la Two subgenomic replicon cell lines can be used for compound characterization in cell culture: one derived from genotype la and one derived from genotype lb. Both replicon constructs are bicistronic subgenomic replicons essentially similar to those described by Bartenschlager and coworkers (Lohmann et al., Science (1999) 285(5424):110-113).
  • the genotype la replicon construct contains the NS3-NS5B coding region derived from the H77 strain of HCV (la-H77) (Blight et al., J Virol (2003) 77(5):3181-3190).
  • the first cistron of the construct consists of the first 36 nucleotides of the HCV la-H77 core gene fused to a firefly luciferase reporter and a neomycin phosphotransferase (Neo) selectable marker.
  • the luciferase and Neo coding regions are separated by the FMDV 2a protease.
  • the second cistron contains the NS3-NS5B coding region derived from la-H77 with the addition of adaptive mutations E1202G in NS3, K1691R in NS4A, and K2040R and S2204I in NS5A.
  • the lb-Con- 1 replicon construct is identical to the la-H77 replicon, except that the 5' and 3' NTRs and the NS3-NS5B coding region can be derived from the lb-Con- 1 strain (Blight et al., Science (2000) 290(5498):1972-1974), and the adaptive mutations are E1202G and T1280I in NS3 and S2204I in NS5A.
  • Replicon cell lines can be maintained in Dulbecco's modified Eagles medium
  • DMEM dimethyl sulfoxide
  • One hundred microliters of medium with the inhibitor can be added to each well of the overnight cell culture plate already containing 100 ⁇ of DMEM with 5% FBS.
  • the medium from the overnight cell culture plates can be replaced with 200 ⁇ DMEM containing 40% human plasma (Innovative Research) plus 5% FBS as well as compound.
  • the cells can be grown for 4 days in tissue culture incubators.
  • the inhibitory effects of compounds against the replicons can be determined by measuring either the level of luciferase or HCV RNA.
  • the luciferase assay can be conducted using a Luciferase Assay System kit (Promega) following the manufacturer's instructions.
  • RNA extractions can be performed using the CellsDirect kit (Invitrogen), and the HCV RNA copy number can be measured using the Superscript III Platinum One- Step qRT-PCR system (Invitrogen) and primers specific to the HCV 5' nontranslated region.
  • Cytotoxicity can be determined by the 3-[4,5-dimethythiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay as follows. Replicon cells is plated in 96- well plates
  • Mutations detected in resistance selection studies can be introduced into wild type transient replicon constructs based on genotypes la-H77 and lb-N. Both replicons are bicistronic sub-genomic constructs containing a firefly luciferase reporter similar to those described above, but they do not contain a Neo selectable marker and are therefore only suitable for transient replication assays.
  • the la-H77 replicon for transient assays further differs from the replicon in the stable cell line in that it contains NS2 through NS5B in the second cistron.
  • the lb-N strain replicon contains NS3 through NS5B in the second cistron, with adaptive mutations E1202G in NS3 and S2204I in NS5A.
  • Mutagenesis can be performed using the Stratagene QuikChange XL II site-directed mutagenesis kit. Mutants' sequences can be confirmed, plasmids can be linearized with Xba I restriction enzyme and used as template for in vitro transcription reactions to make mutant replicon RNA for transient transfections. In vitro transcription can be performed with the T7 Megascript kit (Ambion).
  • Transient replicon transfections can be performed essentially as described by Mo et al. (Antimicrob Agents Chemother (2005) 49(10):4305-4314) with slight modifications. Fifteen micrograms of template RNA can be used to electroporate 3xl0 6 cells in a 200 ⁇ volume in a 0.2 cm cuvette. The cells used for transient transfections can be Huh7 cells obtained by curing replicon-containing cells with IFN (Mo et al., supra). Electroporation can be done with a Gene Pulser II (Bio-Rad, CA) at 480V and 25 ⁇ , using two manual pulses.
  • Gene Pulser II Bio-Rad, CA
  • Transfected cells can be diluted to 7.5x10 4 cells/ml and plated in 96 well plates at 7.5x103 cells per well in DMEM with 5% FBS and 100 IU/ml penicillin, 100 mg/ml streptomycin (Invitrogen). Four hours post-transfection, one plate is harvested for luciferase measurement; this plate may provide a measure of the amount of input RNA that can be translated, and thus of transfection efficiency. To the remaining plates, test compound serial dilutions in DMSO can be added (0.5% DMSO final concentration), and plates are incubated for 4 days.
  • Exemplary compounds of the present invention were tested for their anti-HCV activities. Many of the compounds tested showed unexpected anti-HCV activities, including excellent activities in biochemical assays against HCV proteases representing various HCV genotypes, superior activities in standard HCV replicon assays including activity against la- H77 and lb-conl HCV strains in the absence or presence of 40% human plasma, and/or excellent activities in transient replicon assays against drug-resistant mutants in a number of different HCV genetic backgrounds.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Description

PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE
PROTEASE INHIBITORS
RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional application 61/428,488, filed December 30, 2010, and U.S. Provisional application 61/449,331, filed March 4, 2011. The entire contents of the above applications are incorporated herein by reference.
JOINT RESEARCH AGREEMENT
Inventions described in this application were made by or on behalf of Abbott
Laboratories and Enanta Pharmaceuticals, Inc. whom are parties to a joint research agreement, that was in effect on or before the date such inventions were made and such inventions were made as a result of activities undertaken within the scope of the joint research agreement.
TECHNICAL FIELD
The present invention relates to novel macrocycles having activity against the hepatitis C virus (HCV) and useful in the treatment of HCV infections. More particularly, the invention relates to macrocyclic compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
BACKGROUND OF THE INVENTION HCV is the principal cause of non-A, non-B hepatitis and is an increasingly severe public health problem both in the developed and developing world. It is estimated that the virus infects over 200 million people worldwide, surpassing the number of individuals infected with the human immunodeficiency virus (HIV) by nearly five fold. HCV infected patients, due to the high percentage of individuals inflicted with chronic infections, are at an elevated risk of developing cirrhosis of the liver, subsequent hepatocellular carcinoma and terminal liver disease. HCV is the most prevalent cause of hepatocellular cancer and cause of patients requiring liver transplantations in the western world.
There are considerable barriers to the development of anti-HCV therapeutics, which include, but are not limited to, the persistence of the virus, the genetic diversity of the virus during replication in the host, the high incident rate of the virus developing drug-resistant mutants, and the lack of reproducible infectious culture systems and small-animal models for HCV replication and pathogenesis. In a majority of cases, given the mild course of the infection and the complex biology of the liver, careful consideration must be given to antiviral drugs, which are likely to have significant side effects.
SUMMARY OF THE INVENTION
The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The compounds of the present invention interfere with the life cycle of the hepatitis C virus and are useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
In one aspect, the in a I:
Figure imgf000003_0001
( I )
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein:
J is absent, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, -C(O)-, -O-C(O)-, - N(R3)-C(0)-, -C(S)-, -C(=NR4)-, - S(0)-, -S(02)-, or -N(R3)-;
A is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted carbocyclic; each Ri is independently selected from
(i) halogen, hydroxy, amino, -CN, -CF3, -N3, -N02, -OR4, -SR4, -SOR4, -SO^, -N(R3)S(0)2-R4, -N(R3)(S02)NR3R4, -NR3R4, -C(0)-0_R4, -C(0)R4, - C(0)NR3R4, or -N(R3)C(0)R4;
(ii) optionally substituted aryl;
(iii) optionally substituted heteroaryl;
(iv) optionally substituted heterocyclic;
(v) optionally substituted carbocyclic; or
(vi) optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
wherein at least one of Ri is halogen or -OR^
G is -E-R5;
wherein E is absent; optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; or -0-, -S-, -N(R3)-, -N(R3)S(Op)-, -N(R3)C(0)-, -N(R3)
C(0)S(Op)-, -OS(Op)-, -C(0)S(Op)-, or -C(0)N(R3)S(Op)-;
each p is independently 0, 1, or 2;
R5 is H; optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl;
R3 and R4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen;
L is absent or is selected from optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
j = 0, 1, 2, 3, or 4;
k= 0, 1, 2, or 3;
m = 0, 1, or 2;
n is 1, 2, 3, or 4; and === denotes a carbon-carbon single bond ( H2 ) or double bond
Figure imgf000005_0001
DETAILED DESCRIPTION OF THE INVENTION
Various compounds of the invention demonstrate substantially improved antiviral activity against HCV genotype 3a infections compared to unsubstituted phenanthridine compounds. Various compounds of the invention also demonstrate substantially improved antiviral activity against clinically relevant resistant mutants, especially genotype la R155K and D169V. Such compounds also exhibit improved pharmacokinetic properties, as measured preclinically in animals such as rat or dog.
It is understood that the embodiments of the invention discussed below with respect to the preferred variable selections can be taken alone or in combination with one or more of the other embodiments, or preferred variable selections, of the invention, as if each combination were explicitly listed herein.
In one aspect, the in a I:
Figure imgf000005_0002
( I )
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein:
J is absent, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, -C(O)-, -O-C(O)-, - N(R3)-C(0)-, -C(S)-, -C(=NR4)-, S(O)-, -S(02)-, or -N(R3)-; A is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted carbocyclic;
each Ri is independently selected from
(i) halogen, hydroxy, amino, -CN, -CF3, -N3, -N02, -OR4, -SR4, -SOR4, -S02R4, -N(R3)S(0)2-R4, -N(R3)(S02)NR3R4, -NR^, -C(0)-0_R4, -C(0)R4, - C(0)NR3R4, or -N(R3)C(0)R4;
(ii) optionally substituted aryl;
(iii) optionally substituted heteroaryl;
(iv) optionally substituted heterocyclic;
(v) optionally substituted carbocyclic; or
(vi) optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
wherein at least one of Ri is halogen or -OR^
G is -E-R5;
wherein E is absent; optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; or -0-, -S-, -N(R3)-, -N(R3)S(Op)-, -N(R3)C(0)-, -N(R3)
C(0)S(Op)-, -OS(Op)-, -C(0)S(Op)-, or -C(0)N(R3)S(Op)-;
each p is independently 0, 1, or 2;
R5 is H; optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl;
R3 and R4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen; L is absent or is selected from optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
j = 0, 1, 2, 3, or 4;
k= 0, 1, 2, or 3;
m = 0, 1, or 2;
n is 1, 2, 3, or 4; and enotes a carbon-carbon single bond (
Figure imgf000007_0001
) or double bond
Figure imgf000007_0002
In another aspect, the invention provides a compound of formula Ξ“ :
Figure imgf000007_0003
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein J, A, Ri, G, R5, L, j, k, m, and n are as defined above.
In other embodiments, E is -NHS(O)- or -NHS(02)-, and R5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, or imidazolyl, each of which is optionally substituted. In various embodiments, J is -C(O)- and A is optionally substituted -Ci-C8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, optionally substituted -Ci-C8 alkoxy, optionally substituted heteroaryl, optionally substituted -C3-C12 cycloalkyl, or optionally substituted -C3-Ci2 heterocycloalkyl.
In certain embodiments, k=3, j=l and L is absent.
In various embodiments, each Ri is independently selected from halogen, hydroxy, amino, -CN, -CF3, -N3, -N02, -OR4, -SR4, -SOI , -S02R4, -N(R3)S(02) -R4, -N(R3)
S(02)NR3R4, -NR3R4, -C(0)OR4, -C(0)R4, -C(0)NR3R4, or -N(R3)C(0)R4; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic;
optionally substituted carbocyclic; or optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; wherein at least one Ri is halogen or -OR4.
In a further embodiment, each Ri is independently halogen, hydroxy, amino, -CN, -
CF3, -N3, -N02, -OR4, -SR4, -SOR4, -S02R4, -N(R3)S(02) -R4, -N(R3) S(02)NR3R4, -NR3R4, -C(0)OR4, -C(0)R4, -C(0)NR3R4, or -N(R3)C(0)R4.
Alternatively or additionally, Ri is halogen or
Figure imgf000008_0001
and n is 1, 2 or 3.
In another aspect, the invention provides a compound of formula II,
Figure imgf000008_0002
wherein:
J is absent, -C(O)-, - N(R3)-C(0)-, -C(S)-, or -C(=NR4)-;
A is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, optionally substituted arylalkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted carbocyclic;
each Ri is independently selected from
(i) halogen, hydroxy, amino, -OR4, -N(R3)S(0)2-R4, -N(R3)(S02)NR3R4, - NR3R4, -C(0)-0-R4, -C(0)R4, -C(0)NR3R4, or -N(R3)C(0)R4;
(Ο‹) optionally substituted aryl;
(iii) optionally substituted heteroaryl;
(iv) optionally substituted heterocyclic;
(v) optionally substituted carbocyclic; or
(vi) optionally substituted alkyl, optionally substituted alkenyl, or optionally
substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from 0,
S, or N;
wherein at least one of Ri is halogen or -OR^
R5 is H; optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl;
R3 and R4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted haloalkyl, optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen;
n is 1, 2, 3, or 4; and enotes a carbon-carbon single bond (
Figure imgf000009_0001
) or double bond
Figure imgf000009_0002
In certain embodiments, R5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, or imidazolyl, each of which is optionally substituted. In another embodiment, J is -C(O)- and A is optionally substituted -Ci-C8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, optionally substituted -Ci-C8 alkoxy, optionally substituted heteroaryl, optionally substituted -C3-C12 cycloalkyl, or optionally substituted -C3-Ci2 heterocycloalkyl.
In another embodiment of any as ect of the invention, the invention provides a
compound as described above, wherein
Figure imgf000010_0001
In another embodiment of any aspect of the invention, the invention provides a
compound as described above, wherein
Figure imgf000010_0002
is selected from the following Table 1 :
Table 1
Figure imgf000010_0003
Figure imgf000011_0001
Alternatively or additionally, E is -NH-, -NHS(0)p-, or -NH(C0)S(0)p-, and p is 2. Alternatively or additionally, E is -NHS(0)p-, and p is 2.
Alternatively or additionally, R5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, or imidazolyl, each of which is optionally substituted. In a further embodiment, R5 is optionally substituted cyclopropyl.
Alternatively or additionally, J is -C(O)- or -C(=NR4)-. Preferably, J is -C(O)-.
Alternatively or additionally, m is 1.
Alternatively or additionally, A is optionally substituted -Ci-C8 alkyl, containing 0, 1,
2, or 3 heteroatoms selected from O, S, or N; optionally substituted -Ci-C8 haloalkyl, optionally substituted -Ci-C8 hydroxyalkyl, optionally substituted aryl, optionally substituted -Ci-C8 alkoxy, optionally substituted heteroaryl, optionally substituted -C12 cycloalkyl, or optionally substituted -Ci2 heterocyclyl.
In certain embodiments of any aspect of the invention, A is selected from Me, Et, Pr, i-Pr, Bu, s-Bu, t-Bu,
Figure imgf000011_0002
Figure imgf000012_0001
wherein:
J' is -NHC(O)-, -NHC(0)0-, -C(O)-, -O-C(O)-, -C(S)-, -S(O)-, -S(02)-;
A' is optionally substituted -Ci-C8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted -Ci-C8 haloalkyl, optionally substituted aryl, optionally substituted -Ci-C8 alkoxy, optionally substituted heteroaryl, optionally substituted -C3-C12 cycloalkyl, or optionally substituted -C3-Ci2 heterocyclyl;
R' is H, optionally substituted -Ci-C8 alkyl, optionally substituted -C3-C12 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted -C3-C12 heterocyclyl;
R" is H, optionally substituted -Ci-C8 alkyl, optionally substituted -C3-C12 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted -C3-C12 heterocyclyl; and
t is 0 or 1.
In further embodiments,
J' is -NHC(O)-, or -NHC(0)0-;
A' is optionally substituted -Ci-C8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, or optionally substituted heteroaryl; R' is H, optionally substituted -Q-Q alkyl or optionally substituted -C3-C12 cycloalkyl,
R" is H, and
t is 0 or 1.
In a further embodiment, A' is Me, Et, Pr, i-Pr, Bu, s-Bu, t-Bu, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, imidazolyl,
Figure imgf000013_0001
each of which is optionally substituted.
In a further embodiment, R' is Et, Pr, i-Pr, t-Bu, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydropyran, CH2-i-Pr, CH2-t-Bu, CH2-cyclopropyl, CH2-cyclobutyl, CH2- cyclopentyl, CH2-cyclohexyl, or CH2-tetrahydropyran.
In another embodiment of any aspect of the invention, A is
Figure imgf000013_0002
wherein J" is -NC(O)-, -NC(0)0-, -C(O)-, -O-C(O)-, -C(S)-, -C(=NR4)-, -S(O)-, -S(02)-; and A" is optionally substituted -Ci-C8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted -Ci-C8 haloalkyl, optionally substituted aryl, optionally substituted -Ci-C8 alkoxy, optionally substituted heteroaryl, optionally substituted -C3-C12 cycloalkyl, or optionally substituted -C3-Ci2 heterocyclyl. In a further embodiment, J" is -NC(O)- or -NC(0)0-; and A" is optionally substituted -Ci-Cs alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, or optionally substituted heteroaryl.
In a further embodiment, A" is t-Bu, optionally substituted pyrazine, or optionally substituted isoxazole.
In another embodiment of any aspect of the invention, A is -CHRz(OH)-, wherein Rz is cyclohexyl, i-Pr, i-Bu, t-Bu, or CF3.
In another embodiment of any aspect of the invention, A is CHF2-RY, wherein RY is Ph or Et.
In certain embodiments of any aspect of the invention, E is -N(R3)S(0)p-; -
N(R3)C(0)-, -OS(0)p-, or -C(0)S(0)p-; and p is 2.
In a further embodiment of any aspect of the invention, R5 is optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, R5 is carbocyclic. In a further embodiment, R5 is cyclopropyl, which is optionally substituted.
In another embodiments of any aspect of the invention, J is -C(O)-.
In other embodiments of any aspect of the invention, A is an optionally substituted alkyl, an optionally substituted haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl.
In certain embodiments of any aspect of the invention, A is methyl, ethyl, propyl, iso- propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, heptyl,
Figure imgf000014_0001
Figure imgf000015_0001
In certain embodiments of any aspect of the invention, each Ri is independently selected from H, halogen, hydroxy, amino, -CN, -CF3, -N3, -N02, -OR4, -SR4, -NR3R4, optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; optionally substituted haloalkyl, or optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl; wherein at least one Ri is halogen or -OR4-.
In various embodiments of any aspect of the invention, each R3 and R4 is independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen.
In certain embodiments of any aspect of the invention, G is E-R5, wherein E is - NHS(0)2- and R5 is cyclopropyl, which is optionally substituted.
In another embodiment of each of the above-described aspects of the invention, A is optionally substituted cycloalkyl.
In another embodiment of each of the above-described aspects of the invention, A is optionally substituted heterocyclyl. In another embodiment of each of the above-described aspects of the invention, A is optionally substituted alkyl.
In another embodiment of each of the above-described aspects of the invention A is optionally substituted heteroaryl.
In another embodiment of each of the above-described aspects of the invention A is
Figure imgf000015_0002
other embodiment of each of the above-described aspects of the invention A is
Figure imgf000016_0001
In another embodiment of each of the above-described aspects of the invention A is
CHRz(OH)-.
In another embodiment of each of the above-described aspects of the invention A is
CHF2-RY.
In another embodiment of each of the above-described aspects of the invention, J is - C(O)-; and A is optionally substituted cycloalkyl.
In another embodiment of each of the above-described aspects of the invention, J is - C(O)-; and A is optionally substituted heterocyclyl.
In another embodiment of each of the above-described aspects of the invention, J is - C(O)-; and A is optionally substituted alkyl.
In another embodiment of each of the above-described aspects of the invention J is - C(O)-; and A is optionally substituted heteroaryl. In another embodiment of each of the above-described aspects of the invention J is
Figure imgf000016_0002
-C(O)-; and A is
In another embodiment of each of the above-described aspects of the invention J is
C(O)-; and A is
Figure imgf000016_0003
In another embodiment of each of the above-described aspects of the invention J is C(O)-; and A is -CHRz(OH)- . In another embodiment of each of the above-described aspects of the invention J is - C(O)-; and A is CHF2-RY.
In another embodiment of each of the above-described aspects of the invention, E is NHS(0)2; R5 is cyclopropyl or methyl-substituted cyclopropyl; and A is optionally substituted cycloalkyl.
In another embodiment of each of the above-described aspects of the invention, E is NHS(0)2; R5 is cyclopropyl or methyl-substituted cyclopropyl; and A is optionally substituted heterocyclyl.
In another embodiment of each of the above-described aspects of the invention, E is NHS(0)2; R5 is cyclopropyl or methyl-substituted cyclopropyl; and A is optionally substituted alkyl.
In another embodiment of each of the above-described aspects of the invention E is NHS(0)2; R5 is cyclopropyl or methyl-substituted cyclopropyl; and A is optionally substituted heteroaryl.
In another embodiment of each of the above-described aspects of the invention E is -
NHS(0)2; R5 is cyclopropyl or methyl-substituted cyclopropyl; and A is
Figure imgf000017_0001
In another embodiment of each of the above-described aspects of the invention E is
Figure imgf000017_0002
In another embodiment of each of the above-described aspects of the invention E is NHS(0)2; R5 is cyclopropyl or methyl-substituted cyclopropyl; and A is -CHRz(OH)-.
In another embodiment of each of the above-described aspects of the invention E is NHS(0)2; R5 is cyclopropyl or methyl-substituted cyclopropyl; and A is CHF2-RY. In another embodiment of each of the above-described aspects of the invention, E is NHS(0)2; R5 is cyclopropyl or methyl-substituted cyclopropyl; J is -C(O)-; and A is optionally substituted cycloalkyl.
In another embodiment of each of the above-described aspects of the invention, E is NHS(0)2; R5 is cyclopropyl or methyl-substituted cyclopropyl; J is -C(O)-; and A is optionally substituted heterocyclyl.
In another embodiment of each of the above-described aspects of the invention, E is NHS(0)2; R5 is cyclopropyl or methyl-substituted cyclopropyl; J is -C(O)-; and A is optionally substituted alkyl. In another embodiment of each of the above-described aspects of the invention E is -
NHS(0)2; R5 is cyclopropyl or methyl-substituted cyclopropyl; J is -C(O)-; and A is optionally substituted heteroaryl.
In another embodiment of each of the above-described aspects of the invention E is - NHS(0)2; R5 is cyclopropyl or methyl-substituted cyclopropyl; J is -C(O)-; and A is
Figure imgf000018_0001
In another embodiment of each of the above-described aspects of the invention E is NHS 0)2; R5 is cyclopropyl or methyl-substituted cyclopropyl; J is -C(O)-; and A is
Figure imgf000018_0002
In another embodiment of each of the above-described aspects of the invention E isβ–  NHS(0)2; R5 is cyclopropyl or methyl-substituted cyclopropyl; J is -C(O)-; and A is - CHRz(OH)-.
In another embodiment of each of the above-described aspects of the invention E isβ–  NHS(0)2; R5 is cyclopropyl or methyl-substituted cyclopropyl; J is -C(O)-; and A is CHF2- RY. In of the above-descried aspects and embodiments of the
invention,
Figure imgf000019_0001
selected from the following Table 1 :
Table 1
Figure imgf000019_0002
Figure imgf000020_0001
In certain embodiments, the invention provides a compound of formula III:
Figure imgf000020_0002
( III )
wherein:
A is optionally substituted alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, or optionally substituted heteroaryl;
each Ri is independently selected from halogen, hydroxy, -OR4, -C(0)-0-R4, -
C(0)R4, and -C(0)NR3R4,
wherein at least one of Ri is halogen or -OR4;
Rx is H or optionally substituted alkyl;
R3 and R4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted haloalkyl, optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen; and
n is 1, 2, or 3. In another embodiment, the invention provides a compound as described above,
wherein
Figure imgf000021_0001
invention provides a compound as described above,
wh
Figure imgf000021_0002
selected from the following Table 1 :
Table 1
Figure imgf000021_0003
Figure imgf000022_0001
In various embodiments, A is optionally substituted -Ci-C8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from 0, S, or N; optionally substituted -Ci-C8 haloalkyl, optionally substituted -Ci-C8 hydroxyalkyl, optionally substituted aryl, optionally substituted -Ci-C8 alkoxy, optionally substituted heteroaryl, optionally substituted -C3-C12 cycloalkyl, or optionally substituted -C3-Ci2 heterocyclyl.
Figure imgf000022_0002
In another embodiment, A is
Figure imgf000023_0001
, wherein:
J' is -NHC(O)-, or -NHC(0)0-;
A' is optionally substituted -Ci-C8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, or optionally substituted heteroaryl;
R' is H, optionally substituted -Ci-C8 alkyl or optionally substituted -C3-C12 cycloalkyl,
R" is H, and
t is 0 or 1.
In a further embodiment, A' is Me, Et, Pr, i-Pr, Bu, s-Bu, t-Bu, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, imidazolyl,
Figure imgf000023_0002
each of which is optionally substituted.
In a further embodiment, R' is Et, Pr, i-Pr, t-Bu, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydropyran, CH2-i-Pr, CH2-t-Bu, CH2-cyclopropyl, CH2-cyclobutyl, CH2- cyclopentyl, CH2-cyclohexyl, or CH2-tetrahydropyran.
Figure imgf000024_0001
wherein, J" is -NC(0)- or -NC(0)0-; and A" is optionally substituted -Ci-C8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from 0, S, or N, or optionally substituted heteroaryl.
In a further embodiment, A" is t-Bu, optionally substituted pyrazine, or optionally substituted isoxazole.
In another embodiment, A is -CHRz(OH)-, wherein Rz is cyclohexyl, i-Pr, i-Bu, t-Bu, or CF3.
In another embodiment, A is CHF2-RY, wherein RY is Ph or Et.
In another embodiment, A is optionally substituted cycloalkyl. In another
embodiment, A is optionally substituted heterocyclyl. In another embodiment, A is optionally substituted alkyl. In another embodiment, A is optionally substituted heteroaryl.
Figure imgf000024_0002
Figure imgf000025_0001
is selected from Table 1.
In another embodiment, A is
Figure imgf000025_0002
wherein A' , J', R' R" and t are as defined previously, and
Figure imgf000025_0003
is selected from Table 1.
Figure imgf000025_0004
wherein, J" and A" are previously defined; and
Figure imgf000025_0005
is selected from Table 1.
In another embodiment, A is -CHRz(OH)-, wherein Rz is cyclohexyl, i-Pr, i-Bu, t-Bu, or CF3; and
Figure imgf000025_0006
is selected from Table 1. Representative compounds include, but are not limited to, the following compounds:
Compound nM Assay
0.1-0.5 la stable replicon (nM) 0.1-0.5 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
Figure imgf000026_0001
0.1-0.5 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
Figure imgf000026_0002
0.1-0.5 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
Figure imgf000026_0003
0.1-0.5 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
Figure imgf000027_0001
0.5-1.0 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
0.1-0.5 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
0.5-1.0 la stable replicon (nM)
0.5-1.0 lb stable replicon (nM)
<0.1 la transient replicon (nM)
<0.1 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
Figure imgf000028_0001
0.1-0.5 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
<0.1 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
Figure imgf000028_0002
0.5-1.0 la stable replicon (nM)
0.5-1.0 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
Figure imgf000029_0001
0.1 -0.5 la stable replicon (nM)
<0.1 lb stable replicon (nM)
0.1-0.5 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
0.5-1.0 3a transient replicon (nM)
Figure imgf000030_0001
0.5-1.0 la stable replicon (nM) 0.1-0.5 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) 0.5-1.0 3a transient replicon (nM)
0.5-1.0 la stable replicon (nM)
0.5-1.0 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
0.5-1.0 la stable replicon (nM)
0.5-1.0 lb stable replicon (nM) la transient replicon (nM) lb transient replicon (nM)
>1.0 3a transient replicon (nM)
Figure imgf000031_0001
0.5-1.0 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
<0.1 lb transient replicon (nM)
0.5-1.0 3a transient replicon (nM)
0.5-1.0 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
<0.1 lb transient replicon (nM)
0.5-1.0 3a transient replicon (nM)
0.5-1.0 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
Figure imgf000032_0001
0.1-0.5 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
Figure imgf000032_0002
0.5-1.0 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
>1.0 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
0.5-1.0 la stable replicon (nM) 0.1-0.5 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
Figure imgf000033_0001
0.5-1.0 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
0.5-1.0 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
Figure imgf000034_0001
0.1-0.5 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
0.5-1.0 3a transient replicon (nM)
0.5-1.0 la stable replicon (nM) 0.1-0.5 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
>1.0 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
0.1-0.5 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
0.5-1.0 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
0.5-1.0 la stable replicon (nM) 0.1-0.5 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) <1.0 3a transient replicon (nM)
Figure imgf000035_0001
0.1-0.5 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
Figure imgf000036_0001
0.5-1.0 la stable replicon (nM) 0.1-0.5 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) <1.0 3a transient replicon (nM)
Figure imgf000036_0002
0.1-0.5 la stable replicon (nM) 0.1-0.5 lb stable replicon (nM) la transient replicon (nM) lb transient replicon (nM) n3c = >1.0 3a transient replicon (nM)
0.5-1.0 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
Figure imgf000037_0001
0.1-0.5 la stable replicon (nM)
0.1-0.5 lb stable replicon (nM)
<0.1 la transient replicon (nM)
<0.1 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
0.5-1.0 la stable replicon (nM) 0.1-0.5 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
0.1-0.5 la stable replicon (nM)
<0.1 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM)
3a transient replicon (nM)
Figure imgf000038_0001
0.1-0.5 la stable replicon (nM) <0.1 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM)
3a transient replicon (nM)
0.5-1.0 la stable replicon (nM) 0.1-0.5 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM)
3a transient replicon (nM)
0.5-1.0 la stable replicon (nM)
<0.1 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM)
3a transient replicon (nM)
/
0.5-1.0 la stable replicon (nM) <0.1 lb stable replicon (nM) 0.5-1.0 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM)
3a transient replicon (nM)
0.5-1.0 la stable replicon (nM) <0.1 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.5-1.0 lb transient replicon (nM)
3a transient replicon (nM)
Figure imgf000039_0001
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
Figure imgf000040_0001
0.1-0.5 la stable replicon (nM) 0.1-0.5 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.5-1.0 lb transient replicon (nM) 0.5-1.0 3a transient replicon (nM)
H3C
0.1-0.5 la stable replicon (nM)
<0.1 lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
0.1-0.5 3a transient replicon (nM)
Figure imgf000041_0001
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
/
la stable replicon (nM) lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
0.5-1.0 3a transient replicon (nM)
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) 0.1-0.5 3a transient replicon (nM)
Figure imgf000043_0001
la stable replicon (nM)
<0.1 lb stable replicon (nM) 0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) 0.1-0.5 3a transient replicon (nM)
la stable replicon (nM)
<0.1 lb stable replicon (nM) <0.1 la transient replicon (nM) <0.1 lb transient replicon (nM) 0.1-0.5 3a transient replicon (nM)
Figure imgf000044_0001
H3C
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
Figure imgf000045_0001
Figure imgf000046_0001
ξ„΄ξ„΅ la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) 0.1-0.5 3a transient replicon (nM)
Figure imgf000047_0001
Figure imgf000048_0001
H3C
Figure imgf000049_0001
ξ„΄ξ„Έ
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
la stable replicon (nM) lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
0.1-0.5 3a transient replicon (nM)
Figure imgf000051_0001
la stable replicon (nM) lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
Figure imgf000051_0002
la stable replicon (nM) lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
Figure imgf000052_0001
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) <0.1 3a transient replicon (nM)
Figure imgf000052_0002
la stable replicon (nM) lb stable replicon (nM)
<0.1 la transient replicon (nM) <0.1 lb transient replicon (nM) >1.0 3a transient replicon (nM)
la stable replicon (nM) lb stable replicon (nM)
<0.1 la transient replicon (nM) <0.1 lb transient replicon (nM) 0.1-0.5 3a transient replicon (nM)
Figure imgf000053_0001
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) 0.1-0.5 3a transient replicon (nM)
la stable replicon (nM) lb stable replicon (nM)
0.5-1.0 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) 0.1-0.5 3a transient replicon (nM)
la stable replicon (nM) lb stable replicon (nM)
<0.1 la transient replicon (nM) <0.1 lb transient replicon (nM) 0.5-1.0 3a transient replicon (nM)
Figure imgf000054_0001
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
la stable replicon (nM) lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
>1.0 3a transient replicon (nM)
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) 0.1-0.5 3a transient replicon (nM)
Figure imgf000055_0001
la stable replicon (nM) lb stable replicon (nM)
<0.1 la transient replicon (nM)
0.1-0.5 lb transient replicon (nM)
0.1-0.5 3a transient replicon (nM)
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) 0.5-1.0 3a transient replicon (nM)
la stable replicon (nM) lb stable replicon (nM)
<0.1 la transient replicon (nM) <0.1 lb transient replicon (nM) >1.0 3a transient replicon (nM)
Figure imgf000056_0001
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
Figure imgf000056_0002
la stable replicon (nM) lb stable replicon (nM)
<0.1 la transient replicon (nM) <0.1 lb transient replicon (nM) 0.5-1.0 3a transient replicon (nM)
Figure imgf000057_0001
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
la stable replicon (nM) lb stable replicon (nM)
0.1-0.5 la transient replicon (nM) 0.1-0.5 lb transient replicon (nM) >1.0 3a transient replicon (nM)
Figure imgf000057_0002
la stable replicon (nM) lb stable replicon (nM)
<0.1 la transient replicon (nM) <0.1 lb transient replicon (nM) 0.1-0.5 3a transient replicon (nM)
Figure imgf000058_0001
Figure imgf000059_0001
ξ„΅ξ„Έ
Figure imgf000060_0001
la stable replicon (nM) lb stable replicon (nM)
<0.1 la transient replicon (nM) <0.1 lb transient replicon (nM) >1.0 3a transient replicon (nM)
Figure imgf000060_0002
Figure imgf000061_0001
Figure imgf000062_0001
61
Figure imgf000063_0001
J^
Figure imgf000064_0001
Figure imgf000065_0001
64
Figure imgf000066_0001
65
Figure imgf000067_0001
Figure imgf000068_0001
ξ„Άξ„·
Figure imgf000069_0001
ξ„Άξ„Έ
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
71
Figure imgf000073_0001
72
Figure imgf000074_0001
73
Figure imgf000075_0001
Figure imgf000076_0001
Each compound's anti-HCV activity can be determined by measuring the activity of the luciferase reporter gene in the replicon in the presence of 5% FBS. The luciferase reporter gene, and selectable marker gene for replicons stably maintained in cell lines, is placed under the translational control of the poliovirus IRES instead of the HCV IRES, and HuH-7 cells are used to support the replication of the replicon.
The inhibitory activities of the compounds of the present invention can be evaluated using a variety of assays known in the art. For instance, stable subgenomic replicon cell lines can be used for compound characterization in cell culture, including those derived from genotypes la-H77, lb-N and lb-Conl, obtained from University of Texas Medical Branch, Galveston, TX (la-H77 and lb-N) or Apath, LLC, St. Louis, MO (lb-Conl). Chimeric replicons using the genotype la or lb replicons with insertion of NS3 genes from isolates from humans infected with genotypes la or lb can be used to measure inhitory activity against a panel of the target protein from natural isolates. Chimeric replicons using the genotype la or lb replicons with insertion of NS3 genes from isolates from humans infected with genotypes 3a, 4 or 6 can be used to measure inhitory activity against representatives of those genotypes. The genotype la replicon construct contains the NS3-NS5B coding region derived from the H77 strain of HCV (la-H77). The replicon also has a firefly luciferase reporter and a neomycin phosphotransferase (Neo) selectable marker. These two coding regions, separated by the FMDV 2a protease, comprise the first cistron of the bicistronic replicon construct, with the second cistron containing the NS3-NS5B coding region with addition of adaptive mutations E1202G, K1691R, K2040R and S2204I. The lb-Conl and lb-N replicon constructs are identical to the la-H77 replicon, except that the HCV 5' UTR, 3' UTR, and NS3-NS5B coding region are derived from the lb-Conl or lb-N strain, and the adaptive mutations are K1609E, K1846T and Y3005C for lb-Conl or A1098T, E1202G, and S2204I for lb-N. In addition, the lb-Conl replicon construct contains a poliovirus IRES between the HCV IRES and the luciferase gene. Replicon cell lines can be maintained in Dulbecco's modified Eagles medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS), 100 IU/ml penicillin, 100 mg/ml streptomycin (Invitrogen), and 200 mg/ml G418 (Invitrogen).
The inhibitory effects of the compounds of the invention on HCV replication can also be determined by measuring activity of the luciferase reporter gene encoded by subgenomic replicons not containing the Neo selectable marker, that are transiently expressed in cells. The adaptive mutations encoded by the la-H77, lb-N and lb-Con-1 replicons are the same as listed above. The lb-Conl replicon used for these transient assays contains the NS2-NS5B coding region rather than the NS3-5B coding region. These replicons may encode target NS3 genes as described for stable subgenomic replicons or they may encode amino acid variants that confer varying degrees of susceptibility to the drug. For example, variants could include R155K, D168E or D168V in a genotype la NS3 gene; R155K, A156T or D168V in a genotype lb NS3 gene; S138T, A166T or Q168R in a genotype 3a NS3 gene. For example, cells can be transfected with the replicon by electroporation and seeded into 96 well plates at a density of 5000 cells per well in 100 μΐ DMEM containing 5% FBS. Compounds diluted in dimethyl sulfoxide (DMSO) to generate a 200x stock in a series of eight half-log dilutions can then be further diluted 100-fold in the medium containing 5% FBS and added to the cell culture plates already containing 100 μΐ of DMEM with 5% FBS. After an incubation period of either 3 or 4 days, 30 μΐ of Passive Lysis buffer (Promega) can be added to each well, with incubation for 15 minutes with rocking to lyse the cells. Luciferin solution (100 μΐ, Promega) can be added to each well, and luciferase activity can be measured with a luminometer. The percent inhibition of HCV RNA replication can be calculated for each compound
concentration and the EC50 value can be calculated using nonlinear regression curve fitting to the 4-parameter logistic equation and GraphPad Prism 4 software. Using the above-described assays or similar cell-based replicon assays, representative compounds of the present invention showed significantly inhibitory activities against HCV replication.
In another aspect, the invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound provided herein (e.g. formula I), or a pharmaceutically acceptable salt, ester, or prodrug thereof, in combination with a
pharmaceutically acceptable carrier or excipient. According to another embodiment, the pharmaceutical compositions of the present invention may further contain one or more other anti-HCV agents. Examples of anti-HCV agents include, but are not limited to, oc-interferon; Ξ²-interferon; pegylated interferon-oc; pegylated interferon-lambda; ribavirin; viramidine; R-5158; nitazoxanide; amantadine;
Debio-025, NIM-811; HCV polymerase inhibitors such as R7128, R1626, R4048, T-1106, PSI-7851, PF-00868554, ANA-598, IDX184, IDX102, IDX375, GS-9190, VCH-759, VCH- 916, MK-3281, BCX-4678, MK-3281, VBY708, ANA598, GL59728 or GL60667; BMS- 790052; BMS-791325; BMS-650032; HCV entry, helicase or internal ribosome entry site inhibitors; or other HCV replication inhibitors such as GS-9132, ACH-1095, AP-H005, A- 831, A-689, AZD2836. For further details see S. Tan, A. Pause, Y. Shi, N. Sonenberg,
Hepatitis C Therapeutics: Current Status and Emerging Strategies, Nature Rev. Drug Discov., 1, 867-881 (2002); WO 00/59929 (2000); WO 99/07733 (1999); WO 00/09543 (2000); WO 99/50230 (1999); US5861297 (1999); and US2002/0037998 (2002).
According to an additional embodiment, the pharmaceutical compositions of the present invention may further contain another HCV protease inhibitor, such as telaprevir, boceprevir, ITMN-191, BI-201335, TMC-435, MK-7009, VBY-376, VX-500, VX-813, PHX-B, ACH-1625, IDX136, or IDX316.
In other embodiments, the invention provides a pharmaceutical composition further comprising pegylated interferon, another anti- viral, anti-bacterial, anti-fungal or anti-cancer agent, or an immune modulator, and/or further comprising a cytochrome P450
monooxygenase inhibitor or a pharmaceutically acceptable salt thereof. In certain
embodiments, the cytochrome P450 monooxygenase inhibitor is ritonavir.
In another aspect, the invention provides for the use of a compound of the invention to manufacture an agent for preventing or treating viral infection. In another aspect, the invention provides for the use of a compound of the invention to manufacture an agent for preventing or treating hepatitis C infection. The present invention also contemplates the use of a solvate (e.g., hydrate) of a compound of the invention to manufacture pharmaceutical compositions for preventing or treating hepatitis C infection. As used herein, "solvate" refers to the physical association of a compound of the invention with one or more solvent molecule, whether organic or inorganic. This physical association often includes hydrogen bonding. In certain instances, the solvate is capable of isolation, for example, when one or more solvate molecules are incorporated in the crystal lattice of the crystalline solid. In another embodiment, the compounds or pharmaceutical compositions of the invention are administered with ritonavir, either simultaneously or sequentially. In certain embodiments, a compound or a pharmaceutical composition of the invention is administered in the same composition as ritonavir. In another embodiment, a compound or a
pharmaceutical composition thereof of the invention is administered in a different
composition than ritonavir.
According to yet another embodiment, the pharmaceutical compositions of the present invention may further comprise inhibitor(s) of other targets in the HCV life cycle, including, but not limited to, helicase, polymerase, metalloprotease, CD81, NS5A, cyclophilin, and internal ribosome entry site (IRES).
In one aspect, the invention provides a method of treating a viral infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of the invention described herein (e.g. formula I), or a pharmaceutically acceptable salt, ester or prodrug thereof, or a pharmaceutical composition comprising the same.
According to a further embodiment, the present invention includes methods of treating hepatitis C infections in a subject in need of such treatment by administering to said subject an anti-HCV virally effective amount or an inhibitory amount of the compounds or pharmaceutical compositions of the present invention.
According to another embodiment, the present invention includes methods of treating hepatitis C infections in a subject in need of such treatment by administering to said subject a compound or a pharmaceutical composition of the present invention. The methods can further include administration of an additional therapeutic agent, including another antiviral agent or an anti-HCV agent as described hereinabove. The additional agent can be co-administered (such as concurrently administered or sequentially administered) with a compound (a pharmaceutically acceptable salt, ester or prodrug thereof) or a pharmaceutical composition of the present invention. The additional agent(s) and a compound (or a pharmaceutically acceptable salt, ester or prodrug thereof) of the present invention can be formulated in the same composition, or in different compositions but co-administered concurrently or sequentially. The methods herein can further include the step of identifying that the subject is in need of treatment for hepatitis C infection. The identification can be by subjective (e.g., health care provider determination) or objective (e.g., diagnostic test) means. In one aspect, the invention provides a method of inhibiting the replication of hepatitis C virus, the method comprising contacting a hepatitis C virus with an effective amount of a compound or pharmaceutical composition of the invention.
In another embodiment, the invention provides a method as described above, further comprising administering an additional anti-hepatitis C virus agent. Examples of anti- hepatitis C virus agents include, but are not limited to, oc-interferon; Ξ²-interferon; pegylated interferon-oc; pegylated interferon-lambda; ribavirin; viramidine; R-5158; nitazoxanide;
amantadine; Debio-025, NEVI-811; HCV polymerase inhibitors such as R7128, R1626, R4048, T-1106, PSI-7851, PF-00868554, ANA-598, IDX184, IDX102, IDX375, GS-9190, VCH-759, VCH-916, MK-3281, BCX-4678, MK-3281, VBY708, ANA598, GL59728 or GL60667; BMS-790052; BMS-791325; BMS-650032; HCV entry, helicase or internal ribosome entry site inhibitors; or other HCV replication inhibitors such as GS-9132, ACH- 1095, AP-H005, A-831, A-689, AZD2836. For further details see S. Tan, A. Pause, Y. Shi, N. Sonenberg, Hepatitis C Therapeutics: Current Status and Emerging Strategies, Nature Rev. Drug Discov., 1, 867-881 (2002); WO 00/59929 (2000); WO 99/07733 (1999); WO
00/09543 (2000); WO 99/50230 (1999); US5861297 (1999); and US2002/0037998 (2002). Preferably, a compound or a pharmaceutical composition of the present invention is coadministered with, or used in combination with, pegylated interferon (e.g., pegylated interferon alpha-2a or 2b) and ribavirin. Ritonavir or another cytochrome P450
monooxygenase inhibitor can also be used to enhance the pharmacokinetics of the compound of the present invention. The patient being treated is preferably infected with HCV genotype- 1 (e.g., genotype la or lb). Patients infected with other HCV genotypes, such as genotypes 2, 3, 4, 5 or 6, can also be treated with a compound or a pharmaceutical composition of the present invention.
In another embodiment, the invention provides a method as described above, further comprising administering another HCV protease inhibitor, an HCV polymerase inhibitor, an HCV helicase inhibitor, or an internal ribosome entry site (IRES)inhibitor, such as telaprevir, boceprevir, ITMN-191, BI-201335, TMC-435, MK-7009, VBY-376, VX-500, VX-813, PHX-B, ACH-1625, IDX136, IDX316, pegylated interferon, another anti-viral, anti- bacterial, anti-fungal or anti-cancer agent, or an immune modulator, and/or further comprising a cytochrome P450 monooxygenase inhibitor or a pharmaceutically acceptable salt thereof. In certain embodiments, the cytochrome P450 monooxygenase inhibitor is ritonavir. An additional embodiment of the present invention includes methods of treating biological samples by contacting the biological samples with the compounds of the present invention.
Yet another aspect of the present invention is a process of making any of the compounds delineated herein employing any of the synthetic means delineated herein.
Definitions
Listed below are definitions of various terms used to describe this invention. These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group. The number of carbon atoms in a hydrocarbyl substituent can be indicated by the prefix "Cx-Cy," where x is the minimum and y is the maximum number of carbon atoms in the substituent.
The prefix "halo" indicates that the substituent to which the prefix is attached is substituted with one or more independently selected halogen radicals. For example,
"haloalkyl" means an alkyl substituent wherein at least one hydrogen radical is replaced with a halogen radical.
If a linking element in a depicted structure is "absent", then the left element in the depicted structure is directly linked to the right element in the depicted structure. For example, if a chemical structure is depicted as X-L-Y wherein L is absent, then the chemical structure is X-Y.
The term "alkyl" as used herein, refers to a saturated, straight- or branched-chain hydrocarbon radical typically containing from 1 to 20 carbon atoms. For example, "Ci-C8 alkyl" contains from one to eight carbon atoms. Examples of alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, w-butyl, tert-butyl, neopentyl, n-hexyl, heptyl, octyl radicals and the like.
The term "alkenyl" as used herein, denotes a straight- or branched-chain hydrocarbon radical containing one or more double bonds and typically from 2 to 20 carbon atoms. For example, "C2-C8 alkenyl" contains from two to eight carbon atoms. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, l-methyl-2-buten-l-yl, heptenyl, octenyl and the like.
The term "alkynyl" as used herein, denotes a straight- or branched-chain hydrocarbon radical containing one or more triple bonds and typically from 2 to 20 carbon atoms. For example, "C2-C8 alkynyl" contains from two to eight carbon atoms. Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl and the like.
The term "alkylene" refers to a divalent group derived from a straight or branched saturated hydrocarbyl chain typically containing from 1 to 20 carbon atoms, more typically from 1 to 8 carbon atoms. Representative examples of alkylene include, but are not limited to, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, and -CH2CH(CH3)CH2-.
The term "alkenylene" refers to a divalent unsaturated hydrocarbyl group which may be linear or branched and which has at least one carbon-carbon double bond. An alkenylene group typically contains 2 to 20 carbon atoms, more typically from 2 to 8 carbon atoms. Non-limiting examples of alkenylene groups includeβ€” C(H)=C(H)β€” ,β€” C(H)=C(H)β€” CH2β€” , -C(H)=C(H)-CH2-CH2-, -CH2-C(H)=C(H)-CH2-, -C(H)=C(H)-CH(CH3)-, and -CH2-C(H)=C(H)-CH(CH2CH3)-.
The term "alkynylene" refers to a divalent unsaturated hydrocarbon group which may be linear or branched and which has at least one carbon-carbon triple bond. Representative alkynylene groups include, by way of example, -C≑C-, -C≑C-CH2-, -C≑C-CH2-CH2-, -CH2- C≑C-CH2-, -C≑C-CH(CH3)-, and -CH2-C≑C-CH(CH2CH3)-.
The terms "cycloalkyl," "carbocycle," "carbocyclic" or "carbocyclyl" refer to a) a monovalent group derived from a monocyclic or polycyclic saturated carbocyclic ring compound; or b) a saturated, partially saturated or completely unsaturated ring system containing zero heteroatom ring atom and typically from 3 to 18 carbon ring atoms. A carbocyclyl may be, without limitation, a single ring, or two or more fused rings, or bridged or spiro rings. A carbocyclyl may contain, for example, from 3 to 14 ring members, from 3 to 10 ring members, from 3 to 8 ring members, or from 3 to 6 ring members. A substituted carbocyclyl may have either cis or trans geometry. Representative examples of carbocyclyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl cyclopropyl, cycloheptyl, cyclooctyl,
cyclopentenyl, cyclopentadienyl, cyclohexadienyl, adamantyl, decahydro-naphthalenyl, octahydro-indenyl, cyclohexenyl, phenyl, naphthyl, fluorenyl, indanyl, 1,2,3,4-tetrahydro- naphthyl, indenyl, isoindenyl, bicyclodecanyl, anthracenyl, phenanthrene, benzonaphthenyl (also known as "phenalenyl"), decalinyl, and norpinanyl and the like. A carbocyclyl group can be attached to the parent molecular moiety through any substitutable carbon atom of the group. The term "aryl" refers to an aromatic carbocyclyl containing from 6 to 14 carbon ring atoms. Non-limiting examples of aryls include phenyl, naphthalenyl, anthracenyl, and indenyl and the like. An aryl group can be connected to the parent molecular moiety through any substitutable carbon atom of the group.
The term "aralkyl" or "arylalkyl" refers to an alkyl residue attached to an aryl ring.
Examples of aralkyl include, but are not limited to, benzyl, phenethyl and the like.
The term "heteroaryl" means an aromatic heterocyclyl typically containing from 5 to 18 ring atoms. A heteroaryl may be a single ring, or two or more fused rings. Non-limiting examples of five-membered heteroaryls include imidazolyl; furanyl; thiophenyl (or thienyl or thiofuranyl); pyrazolyl; oxazolyl; isoxazolyl; thiazolyl; 1,2,3-, 1,2,4-, 1,2,5-, and
1,3,4-oxadiazolyl; and isothiazolyl. Non-limiting examples of six-membered heteroaryls include pyridinyl; pyrazinyl; pyrimidinyl; pyridazinyl; and 1,3,5-, 1,2,4-, and 1,2,3-triazinyl. Non-limiting examples of 6/5-membered fused ring heteroaryls include benzothiofuranyl, isobenzothiofuranyl, benzisoxazolyl, benzoxazolyl, purinyl, and anthranilyl. Non-limiting examples of 6/6-membered fused ring heteroaryls include quinolinyl; isoquinolinyl; and benzoxazinyl (including cinnolinyl and quinazolinyl).
The term "heteroaralkyl" or "heteroarylalkyl" refers to an alkyl residue attached to a heteroaryl ring. Examples include, but are not limited to, pyridinylmethyl, pyrimidinylethyl and the like.
The term "heterocycloalkyl" refers to a non-aromatic 3-, 4-, 5-, 6- or 7-membered ring or a bi- or tri-cyclic group fused system, where (i) each ring contains between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, (ii) each 5-membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (iii) the nitrogen and sulfur heteroatoms may optionally be oxidized, (iv) the nitrogen heteroatom may optionally be quaternized, and (iv) any of the above rings may be fused to a benzene ring. Representative heterocycloalkyl groups include, but are not limited to, [l,3]dioxolane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl and the like.
The terms "heterocyclic" or "heterocyclo" or "heterocyclyl" refer to a saturated (e.g.,
"heterocycloalkyl"), partially unsaturated (e.g., "heterocycloalkenyl" or
"heterocycloalkynyl") or completely unsaturated (e.g., "heteroaryl") ring system typically containing from 3 to 18 ring atoms, where at least one of the ring atoms is a heteroatom (i.e., nitrogen, oxygen or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, nitrogen, oxygen and sulfur. A heterocyclyl group can be linked to the parent molecular moiety via any substitutable carbon or nitrogen atom in the group, provided that a stable molecule results. A heterocyclyl may be, without limitation, a single ring, which typically contains from 3 to 14 ring atoms, from 3 to 8 ring atoms, from 3 to 6 ring atoms, or from 5 to 6 ring atoms. Non-limiting examples of single-ring
heterocyclyls include furanyl, dihydrofuranyl, pyrrolyl, isopyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, isoimidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, triazolyl, tetrazolyl, dithiolyl, oxathiolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, thiodiazolyl, oxathiazolyl, oxadiazoly, pyranyl, dihydropyranyl, pyridinyl, piperidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, triazinyl, isoxazinyl, oxazolidinyl, isoxazolidinyl, oxathiazinyl, oxadiazinyl, morpholinyl, azepinyl, oxepinyl, thiepinyl, or diazepinyl. A heterocyclyl may also include, without limitation, two or more rings fused together, such as, for example, naphthyridinyl, thiazolpyrimidinyl, thienopyrimidinyl, pyrimidopyrimidinyl, or
pyridopyrimidinyl. A heterocyclyl may comprise one or more sulfur atoms as ring members; and in some cases, the sulfur atom(s) is oxidized to SO or S02. The nitrogen heteroatom(s) in a heterocyclyl may or may not be quaternized, and may or may not be oxidized to N-oxide. In addition, the nitrogen heteroatom(s) may or may not be N-protected.
The terms "optionally substituted", "optionally substituted alkyl," "optionally substituted "optionally substituted alkenyl," "optionally substituted alkynyl", "optionally substituted carbocyclic," "optionally substituted aryl", " optionally substituted heteroaryl," "optionally substituted heterocyclic," and any other optionally substituted group as used herein, refer to groups that are substituted or unsubstituted by independent replacement of one, two, or three or more of the hydrogen atoms thereon with substituents including, but not limited to:
-F, -CI, -Br, -I,
-OH, protected hydroxy, alkoxy, oxo, thiooxo,
-N02, -CN, CF3, N3,
-NH2, protected amino, -NH alkyl, -NH alkenyl, -NH alkynyl, -NH cycloalkyl, -NH - aryl, -NH -heteroaryl, -NH -heterocyclic, -dialkylamino, -diarylamino, -diheteroarylamino,
-O- alkyl, -O- alkenyl, -O- alkynyl, -O- cycloalkyl, -O-aryl, -O-heteroaryl, -O- heterocyclic, -C(O)- alkyl, -C(O)- alkenyl, -C(O)- alkynyl, -C(O)- cycloalkyl, -C(0)-aryl, -C(O)- heteroaryl, -C(0)-heterocycloalkyl,
-CONH2, -CONH- alkyl, -CONH- alkenyl, -CONH- alkynyl, -CONH- cycloalkyl, - CONH-aryl, -CONH-heteroaryl, -CONH-heterocycloalkyl,
-OCO2- alkyl, -OC02- alkenyl, -OC02- alkynyl, -OC02- cycloalkyl, -OC02-aryl, -
OC02-heteroaryl, -OC02-heterocycloalkyl, -OCONH2, -OCONH- alkyl, -OCONH- alkenyl, - OCONH- alkynyl, -OCONH- cycloalkyl, -OCONH- aryl, -OCONH- heteroaryl, -OCONH- heterocycloalkyl,
-NHC(O)- alkyl, -NHC(O)- alkenyl, -NHC(O)- alkynyl, -NHC(O)- cycloalkyl, - NHC(0)-aryl, -NHC(0)-heteroaryl, -NHC(0)-heterocycloalkyl, -NHC02- alkyl, -NHC02- alkenyl, -NHC02- alkynyl, -NHC02 -cycloalkyl, -NHC02- aryl, -NHC02- heteroaryl, - NHC02- heterocycloalkyl, -NHC(0)NH2, -NHC(0)NH- alkyl, -NHC(0)NH- alkenyl, - NHC(0)NH- alkenyl, -NHC(0)NH- cycloalkyl, -NHC(0)NH-aryl, -NHC(0)NH-heteroaryl, -NHC(0)NH-heterocycloalkyl, NHC(S)NH2, -NHC(S)NH- alkyl, -NHC(S)NH- alkenyl, - NHC(S)NH- alkynyl, -NHC(S)NH- cycloalkyl, -NHC(S)NH-aryl, -NHC(S)NH-heteroaryl, - NHC(S)NH-heterocycloalkyl, -NHC(NH)NH2, -NHC(NH)NH- alkyl, -NHC(NH)NH- - alkenyl, -NHC(NH)NH- alkenyl, -NHC(NH)NH- cycloalkyl, -NHC(NH)NH-aryl, - NHC(NH)NH-heteroaryl, -NHC(NH)NH-heterocycloalkyl, -NHC(NH)- alkyl, -NHC(NH)- alkenyl, -NHC(NH)- alkenyl, -NHC(NH)- cycloalkyl, -NHC(NH)-aryl, -NHC(NH)- heteroaryl, -NHC(NH)-heterocycloalkyl,
-C(NH)NH- alkyl, -C(NH)NH- alkenyl, -C(NH)NH- alkynyl, -C(NH)NH- cycloalkyl, -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NH-heterocycloalkyl,
-S(O)- alkyl, - S(O)- alkenyl, - S(O)- alkynyl, - S(O)- cycloalkyl, - S(0)-aryl, - S(O)- heteroaryl, - S(0)-heterocycloalkyl -S02NH2, -S02NH- alkyl, -S02NH- alkenyl, -S02NH- alkynyl, -S02NH- cycloalkyl, -S02NH- aryl, -S02NH- heteroaryl, -S02NH- heterocycloalkyl,
-NHS02- alkyl, -NHS02- alkenyl, - NHS02- alkynyl, -NHS02- cycloalkyl, -NHS02- aryl, -NHS02-heteroaryl, -NHS02-heterocycloalkyl, -CH2NH2, -CH2S02CH3,
-alkyl, -alkenyl, -alkynyl, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, - heterocycloalkyl, -cycloalkyl, -carbocyclic, -heterocyclic, polyalkoxyalkyl, polyalkoxy, - methoxymethoxy, -methoxyethoxy, -SH, -S- alkyl, -S- alkenyl, -S- alkynyl, -S- cycloalkyl, - S-aryl, -S-heteroaryl, -S-heterocycloalkyl, or methylthiomethyl.
It is understood that the aryls, heteroaryls, carbocyclics, heterocyclics, alkyls, and the like can be further substituted. The terms "halo" and "halogen," as used herein, refer to an atom selected from fluorine, chlorine, bromine and iodine.
The term "subject" as used herein refers to a mammal. A subject therefore refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, and the like. Preferably the subject is a human. When the subject is a human, the subject may be either a patient or a healthy human.
The term "hydroxy activating group", as used herein, refers to a labile chemical moiety which is known in the art to activate a hydroxy group so that it will depart during synthetic procedures such as in a substitution or elimination reactions. Examples of hydroxy activating group include, but not limited to, mesylate, tosylate, triflate, p-nitrobenzoate, phosphonate and the like.
The term "leaving group," or "LG", as used herein, refers to any group that leaves in the course of a chemical reaction involving the group and includes but is not limited to halogen, brosylate, mesylate, tosylate, triflate, p-nitrobenzoate, phosphonate groups, for example.
The term "protected hydroxy," as used herein, refers to a hydroxy group protected with a hydroxy protecting group, as defined above, including benzoyl, acetyl, trimethylsilyl, triethylsilyl, methoxymethyl groups, for example.
The term "hydroxy protecting group," as used herein, refers to a labile chemical moiety which is known in the art to protect a hydroxy group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the hydroxy protecting group as described herein may be selectively removed. Hydroxy protecting groups as known in the are described generally in T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of hydroxy protecting groups include benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4- bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, methoxycarbonyl, tert- butoxycarbonyl, isopropoxycarbonyl, diphenylmethoxycarbonyl, 2,2,2- trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, 2-furfuryloxycarbonyl, allyloxycarbonyl, acetyl, formyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, t-butyl, 2,2,2-trichloroethyl, 2-trimethylsilyl ethyl, l,l-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, para-methoxybenzyldiphenylmethyl,
triphenylmethyl(trityl), tetrahydrofuryl, methoxymethyl, methylthiomethyl,
benzyloxymethyl, 2,2,2-triehloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, para-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, and the like. Preferred hydroxy protecting groups for the present invention are acetyl (Ac or - C(0)CH3), benzoyl (Bz or -C(0)C6H5), and trimethylsilyl (TMS or -Si(CH3)3).
The term "amino protecting group," as used herein, refers to a labile chemical moiety which is known in the art to protect an amino group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the amino protecting group as described herein may be selectively removed. Amino protecting groups as known in the are described generally in T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of amino protecting groups include, but are not limited to, t-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, and the like.
The term "protected amino," as used herein, refers to an amino group protected with an amino protecting group as defined above.
The term "alkylamino" refers to a group having the structure -N(RaRb), where Ra and Rb are independent H or alkyl.
The term "acyl" includes residues derived from acids, including but not limited to carboxylic acids, carbamic acids, carbonic acids, sulfonic acids, and phosphorous acids. Examples include aliphatic carbonyls, aromatic carbonyls, aliphatic sulfonyls, aromatic sulfinyls, aliphatic sulfinyls, aromatic phosphates and aliphatic phosphates. Examples of aliphatic carbonyls include, but are not limited to, acetyl, propionyl, 2-fluoroacetyl, butyryl, 2-hydroxy acetyl, and the like.
As used herein, the term "pharmaceutically acceptable salt" refers to those salts of the compounds formed by the process of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are
commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). The salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. Examples of pharmaceutically acceptable salts include, but are not limited to, nontoxic acid addition salts, or salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate,
cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, or magnesium salts, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.
As used herein, the term "pharmaceutically acceptable ester" refers to esters of the compounds formed by the process of the present invention which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.
The term "pharmaceutically acceptable prodrugs" as used herein refers to those prodrugs of the compounds formed by the process of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like,
commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present invention. "Prodrug", as used herein means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to afford any compound delineated by the formulae of the instant invention. Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al. (ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al., (ed). "Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991); Bundgaard, et al., Journal of Drug Deliver Reviews, 8:1-38(1992); Bundgaard, J. of Pharmaceutical Sciences, 77:285 et seq. (1988); Higuchi and Stella (eds.) Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975); and Bernard Testa & Joachim Mayer, "Hydrolysis In Drug And Prodrug Metabolism: Chemistry, Biochemistry And Enzymology," John Wiley and Sons, Ltd. (2002).
This invention also encompasses pharmaceutical compositions containing, and methods of treating viral infections through administering, pharmaceutically acceptable prodrugs of compounds of the invention. For example, compounds of the invention having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the invention. The amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxyysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma- aminobutyric acid, citrulline, homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxyl groups can be derivatized as amides or alkyl esters. Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxy carbonyls, as outlined in Advanced Drug Delivery Reviews, 1996, 19, 1 15. Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers wherein the acyl group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed. Prodrugs of this type are described in J. Med. Chem. 1996, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term "stable", as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject).
Pharmaceutical Compositions
The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers. As used herein, the term "pharmaceutically acceptable carrier" means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The pharmaceutical
compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, or as an oral or nasal spray.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water, alcohol or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, polysorbate, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), mono- or di- glycerides, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, antioxidants, sweetening, flavoring, and perfuming agents. The liquid dosage form can also be
encapsulated in a gelatin capsule, wherein a compound of the present invention can be dissolved in a pharmaceutically acceptable carrier containing, for example, one or more solubilizating agents (e.g., polysorbate 80 and mono and diglycerides), and other suitable excipients (e.g., an antioxidants such as ascorbyl palmitate, or a sweetening or flavoring agent).
Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S. P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Immediate release forms are also contemplated by the present invention.
Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
The active compounds can also be in micro-encapsulated form with one or more excipients as noted above
The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
According to the methods of treatment of the present invention, viral infections are treated or prevented in a subject, such as a human or another animal, by administering to the subject a therapeutically effective amount of a compound of the invention (or a
pharmaceutically acceptable salt, ester or prodrug thereof), in such amounts and for such time as is necessary to achieve the desired result. The term "therapeutically effective amount" of a compound of the invention, as used herein, means a sufficient amount of the compound so as to decrease the viral load in a subject and/or decrease the subject's HCV symptoms. As is well understood in the medical arts a therapeutically effective amount of a compound of this invention will be at a reasonable benefit/risk ratio applicable to any medical treatment.
Antiviral Activity
An inhibitory amount or dose of the compounds of the present invention may range from about 0.1 mg/Kg to about 500 mg/Kg, alternatively from about 1 to about 50 mg/Kg. Inhibitory amounts or doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents.
According to the methods of treatment of the present invention, viral infections are treated or prevented in a subject such as a human or lower mammal by administering to the subject an anti-hepatitis C virally effective amount or an inhibitory amount of a compound of the present invention, in such amounts and for such time as is necessary to achieve the desired result. An additional method of the present invention is the treatment of biological samples with an inhibitory amount of a compound of composition of the present invention in such amounts and for such time as is necessary to achieve the desired result.
The term "anti-hepatitis C virally effective amount" of a compound of the invention, as used herein, means a sufficient amount of the compound so as to decrease the viral load in a biological sample or in a subject. As well understood in the medical arts, an anti-hepatitis C virally effective amount of a compound of this invention will be at a reasonable benefit/risk ratio applicable to any medical treatment.
The term "inhibitory amount" of a compound of the present invention means a sufficient amount to decrease the hepatitis C viral load in a biological sample or a subject. It is understood that when said inhibitory amount of a compound of the present invention is administered to a subject it will be at a reasonable benefit/risk ratio applicable to any medical treatment as determined by a physician. The term "biological sample(s)," as used herein, means a substance of biological origin intended for administration to a subject. Examples of biological samples include, but are not limited to, blood and components thereof such as plasma, platelets, subpopulations of blood cells and the like; organs such as kidney, liver, heart, lung, and the like; sperm and ova; bone marrow and components thereof; or stem cells. Thus, another embodiment of the present invention is a method of treating a biological sample by contacting said biological sample with an inhibitory amount of a compound or pharmaceutical composition of the present invention.
Upon improvement of a subject's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary.
Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. The subject may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific inhibitory dose for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
The total daily inhibitory dose of the compounds of this invention administered to a subject in single or in divided doses can be in amounts, for example, from 0.01 to 50 mg/kg body weight or more usually from 0.1 to 25 mg/kg body weight. Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose. In one embodiment, treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the
compound(s) of this invention per day in single or multiple doses. In another embodiment, the treatment regimen comprises administration to a patient in need of such treatment from about 25 mg to about 6000 mg of a compound(s) of this invention per day in single or multiple doses, either with or without a cytochrome P450 monooxygenase inhibitor such as ritonavir. The suitable daily dose for the co-administered cytochrome P450 monooxygenase inhibitor (e.g., ritonavir) can range, without limitation, from 10 to 200 mg. Preferably, a compound(s) of the present invention, or a combination of a compound(s) of the invention and ritonavir, is administered once daily or twice daily to achieve the desired daily dose amount. For instance, when used without ritonavir, a compound of the present invention can be administered to a patient twice a day with a total daily dose of 4000, 4200, 4400, 4600, 4800 or 5000 mg. For another instance, when used in combination with ritonavir, a compound of the present invention can be administered to a patient once or twice a day with a total daily dose of 200, 400, 600 or 800 mg, where the amount of ritonavir can be 25, 50 or 100 mg per administration. Synthetic Methods
The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes that illustrate the methods by which the compounds of the invention may be prepared.
Definitions of variables in the structures in the schemes herein are commensurate with those of corresponding positions in the formulae delineated herein.
A method of producing a compound of formula I, or a pharmaceutically acceptable salt, ester or prodrug thereof, comprising the step of reacting a compound of formula X:
Figure imgf000095_0001
(X);
wherein,
J is absent, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, -C(O)-, -O-C(O)-, - N(R3)-C(0)-, -C(S)-, -C(=NR4)-, - S(0)-, -S(02)-, or -N(R3)-;
A is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted carbocyclic;
G is -E-R5;
wherein E is absent; optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; or -0-, -S-, -N(R3)-, -N(R3)S(Op)-, -N(R3)C(0)-, -N(R3)
C(0)S(Op)-, -OS(Op)-, -C(0)S(Op)-, or -C(0)N(R3)S(Op)-;
each p is independently 0, 1, or 2; R5 is H; optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl;
R3 and R4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen;
L is absent or is selected from optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
j = 0, 1, 2, 3, or 4;
k= 0, 1, 2, or 3;
m = 0, 1, or 2; es a carbon-carbon single bond (
Figure imgf000096_0001
) or double bond
Figure imgf000096_0002
LG is a leaving group;
compound of formul
Figure imgf000096_0003
wherein:
each Ri is independently selected from
(vi) halogen, hydroxy, amino, -CN, -CF3, -N3, -N02, -OR4, -SR4, -SOR4, -SO^, -N(R3)S(0)2-R4, -N(R3)(S02)NR3R4, -NR^, -C(0)-0_R4, -C(0)R4, - C(0)NR3R4, or -N(R3)C(0)R4;
(vii) optionally substituted aryl; (viii) optionally substituted heteroaryl;
(ix) optionally substituted heterocyclic;
(x) optionally substituted carbocyclic; or
(vi) optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
wherein at least one of Ri is halogen or -OR4-; and
n is 1, 2, 3, or 4;
to thereby produce a compound of formula I.
The compounds described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- , or as (D)- or (L)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optical isomers may be prepared from their respective optically active precursors by the procedures described above, or by resolving the racemic mixtures. The resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known to those skilled in the art. Further details regarding resolutions can be found in Jacques, et al., Enantiomers, Racemates, and Resolutions (John Wiley & Sons, 1981). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included. The configuration of any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration unless the text so states; thus a carbon- carbon double bond depicted arbitrarily herein as trans may be cis, trans, or a mixture of the two in any proportion.
The synthesized compounds can be separated from a reaction mixture and further purified by a method such as column chromatography, high pressure liquid chromatography, or recrystallization. As can be appreciated by the skilled artisan, further methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. In addition, the solvents, temperatures, reaction durations, etc. delineated herein are for purposes of illustration only and one of ordinary skill in the art will recognize that variation of the reaction conditions can produce the desired bridged macrocyclic products of the present invention. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH
Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.
The compounds of this invention may be modified by appending various
functionalities via any synthetic means delineated herein to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
Examples
The compounds and processes of the present invention will be better understood in connection with the following examples, which are intended as an illustration only and not to limit the scope of the invention. The following examples can be prepared according to either Scheme 1 or Scheme 2 as described above. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art and such changes and modifications including, without limitation, those relating to the chemical structures, substituents, derivatives, formulations and/or methods of the invention may be made without departing from the spirit of the invention and the scope of the appended claims.
Example 1. N-((2R,6S,13aS,14aR,16aS,Z)-2-(3-fluorophenanthridin-6-yloxy)-14a-(l- methylcyclopropylsulfonylcarbamoyl)-5,16-dioxo- l,2,3,5,6,7,8,9,10,ll,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[l,2- a][l,4]diazacyclopentadecin-6-yl)-5-methylisoxazole-3-carboxamide
Figure imgf000099_0001
Example la. 3-Fluorophenanthridin-6-ol
Figure imgf000099_0002
1 a
A mixture of 2-(ethoxycarbonyl)phenylboronic acid (7.0 g, 39 mmol), 2-bromo-5- fluoroaniline (7.4 g, 39 mmol), dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (S- Phos, 0.32 g, 0.78 mmol), sodium acetate (4.1 g, 39 mmol), and palladium acetate (0.087 g, 0.39 mmol) in 18 ml. of ethanol was heated with stirring at 80Β° C for 18 h. Additional 2- (ethoxycarbonyl)phenylboronic acid (2.0 g), S-Phos (0.095 g), palladium acetate (0.020 g), and sodium carbonate (1.2 g) was added and the mixture was stirred for 18 h. The solvent was removed by evaporation under reduced pressure, and the resulting solid was isolated by vacuum filtration, washing the remaining solid with water and then hexane. The remaining solid and dried in vacuo @ 50Β° C to provide the title compound (4.39 g, 53% yield) which was used without further purification.
Example lc. (2R,6S,13aS,14aR,16aS,Z)-ethyl 6-(tert-butoxycarbonylamino)-2-(3- fluorophenanthridin-6-yloxy)-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylate
Figure imgf000100_0001
A mixture of (2R,6S,13aS,14aR,16aS,Z)-ethyl 2-(4-bromophenylsulfonyloxy)-6-(tert- butoxycarbonylamino)-5,16-dioxo- 1,2,3,5, 6,7, 8,9, 10, 11, 13a, 14,14a, 15, 16, 16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylate (lb, 2.3 g, 3.2 mmol), 3-fluorophenanthridin-6-ol (Example la, 0.688 g, 3.23 mmol) and cesium carbonate (1.2 g, 3.6 mmol) in dimethylformamide (32 ml) was heated @ 80 Β°C for 5 h. The reaction mixture was cooled to room temperature and partitioned between ethyl acetate and 2 N HC1. The organic phase was washed with water and then saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, and evaporated. The resulting solid was purified by flash chromatography on silica gel, eluting with acetone/hexane, to provide the title compound (1.3 g, 60% yield).
Example Id. (2R,6S,13aS,14aR,16aS,Z)-ethyl 6-amino-2-(3-fluorophenanthridin-6-yloxy)- 5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylate hydrochloride
Figure imgf000101_0001
A solution of (2R,6S,13aS,14aR,16aS,Z)-ethyl 6-(tert-butoxycarbonylamino)-2-(3- fluorophenanthridin-6-yloxy)-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylate
(Example lc, 1.3g, 1.9 mmol) in 1 N HCl (4.7 ml, 19 mmol) was stirred at room temperature for 2 h. The reaction mixture was diluted with chloroform and toluene and evaporated to provide the title compound (1.11 g, quantitative yield) as a colorless solid. This material was used without further purification.
Example le. (2R,6S,13aS,14aR,16aS,Z)-ethyl 2-(3-fluorophenanthridin-6-yloxy)-6-(5- methylisoxazole-3-carboxamido)-5,16-dioxo-l, 2,3,5, 6,7, 8,9, 10,11, 13a,14,14a,15, 16, 16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylate
Figure imgf000101_0002
A mixture of (2R,6S,13aS,14aR,16aS,Z)-ethyl 6-amino-2-(3-fluorophenanthridin-6-yloxy)- 5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylate (Example Id, 1.11 g, 1.89 mmol) was dissolved in dimethylformamide (19 mL) and treated with N-methylmorpholine (0.73 ml, 6.6 mmol) followed by 5-methylisoxazole-3-carboxylic acid (0.264 g, 2.074 mmol) and HATU (0.860 g, 2.263 mmol). The reaction mixture was stirred at room temperature for 1 h, diluted with 2 N HCl and extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel, eluting with acetone/hexane, to provide the title compound (0.94 g, 72% yield)
Example If. (2R,6S,13aS,14aR,16aS,Z)-2-(3-fluorophenanthridin-6-yloxy)-6-(5- methylisoxazole-3-carboxamido)-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylic acid
Figure imgf000102_0001
(2R,6S,13aS,14aR,16aS,Z)-ethyl 2-(3-fluorophenanthridin-6-yloxy)-6-(5-methylisoxazole-3- carboxamido)-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylate (846 mg, 1.21 mmol) was dissolved in tetrahydrofuran (6 mL), methanol (3 mL) , and water (3 mL) and lithium hydroxide monohydrate (76 mg, 1.8 mmol) was added. The reaction mixture was heated at 40 Β°C for 4 h. The mixture was cooled to rt and partitioned between 2 N HC1 and dichloromethane. The organic layer was concentrated under reduced pressure and then azeoptroped with toluene and chloroform to provide the title compound (0.812 g, quantitative yield) as a colorless solid that was used without further purification.
Example 1. N-((2R,6S,13aS,14aR,16aS,Z)-2-(3-fluorophenanthridin-6-yloxy)-14a-(l- methylcyclopropylsulfonylcarbamoyl)-5,16-dioxo-
1,2,3,5, 6,7, 8,9, 10,11, 13a,14,14a,15, 16, 16a-hexadecahydrocyclopropa[e]pyrrolo[l, 2- a][l,4]diazacyclopentadecin-6-yl)-5-methylisoxazole-3-carboxamide
Figure imgf000103_0001
The product of Example If, (2R,6S,13aS,14aR,16aS,Z)-2-(3-fluorophenanthridin-6-yloxy)-6- (5-methylisoxazole-3-carboxamido)-5, 16-dioxo-l, 2,3,5, 6,7, 8,9, 10,1 l,13a,14,14a,15, 16, 16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylic acid (0.812 g, 1.21 mmol) was dissolved in dichloroethane (12 mL) and 4A sieves were added to the flask. To this mixture was added carbonyldiimidazole (505 mg, 3.11 mmol) and the reaction mixture was heated at 40 Β°C for 2 h. The reaction mixture was cooled to room temperature and 1-methylcyclopropane-l- sulfonamide (426 mg, 3.15 mmol) was added followed by 1,8-diazabicycloundecene (0.548 ml, 3.64 mmol). The reaction mixture was stirred at room temperature for 3 h. and then cooled to 0 Β°C and 4 N HCl in dioxane (2.5 mL, 10 mmol) was added. The resulting solid was washed copiously with dichloromethane and the filtrate was washed with 2 N HCl and then water. The organic layer was dried over anhydrous magnesium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with acetone/hexane followed by acetone/chloroform to provide the title compound (0.45 g, 47% yield) as a white solid.
MS(ESI): m/z = 787.2 [M+H]+.
Figure imgf000104_0001
Example lg. (2R,6S,13aS,14aR,16aS,Z)-6-(tert-butoxycarbonylamino)-2-(3- fluorophenanthridin-6-yloxy)-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylic
Figure imgf000104_0002
A mixture of (2R,6S,13aS,14aR,16aS,Z)-ethyl 6-(tert-butoxycarbonylamino)-2-(3- fluorophenanthridin-6-yloxy)-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylate (0.90 g, 1.3 mmol, Example lc) and lithium hydroxide monohydrate (0.384 g, 9.15 mmol) was dissolved in tetrahydrofuran (6.5 mL), methanol (3.3 mL), and water (3.3 mL) and heated to 50 Β°C for 2 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to remove all tetrahydrofuran and methanol. The mixture was diluted with 2 N HCl and the resulting solid was collected by filtration and dried on high vacuum overnight to provide the title compound (0.73 g, 85% yield) as a white solid. This material was taken forward without additional purification.
Example lh. tert-butyl (2R,6S,13aS,14aR,16aS,Z)-2-(3-fluorophenanthridin-6-yloxy)-14a-(l- methylcyclopropylsulfonylcarbamoyl)-5,16-dioxo-
1,2,3, 5,6,7, 8, 9, 10, 11, 13a, 14,14a, 15,16, 16a-hexadecahydrocyclopropa[e]pyrrolo[l, 2- a][l,4]diazacyclopentadecin-6-ylcarbamate
Figure imgf000105_0001
The product of example lg ((2R,6S,13aS,14aR,16aS,Z)-6-(tert-butoxycarbonylamino)-2-(3- fluorophenanthridin-6-yloxy)-5,16-dioxo- 1,2,3,5, 6,7, 8,9, 10,11, 13a,14, 14a, 15, 16, 16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylic acid (3.0 g, 4.5 mmol)) was dissolved in dichloroethane (45 mL) and crushed 3 A molecular sieves (3 g) were added and the mixture stirred for 15 min at room temperature. Carbonyl diimidazole (1.91 g, 11.8 mmol) was added and the reaction mixture was heated to 40 Β°C for 2 h. The reaction mixture was cooled to room temperature and 1-methylcyclopropane-l- sulfonamide (1.60 g, 11.8 mmol) was added. DBU (2.07 g, 13.6 mmol) was then added and the reaction mixture was stirred at room temperature for 16 h. The reaction mixture was filtered through Celite and rinsed with ethyl acetate, and the filtrate was washed with 1 N HC1. The resulting organic phase was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with chloroform/ethyl acetate (3:1) to provide the title compound (3.0 g, 86% yield) as a white solid. Example li. (2R,6S,13aS,14aR,16aS,Z)-6-amino-2-(3-fluorophenanthridin-6-yloxy)-N-(l- methylcyclopropylsulfonyl)-5,16-dioxo- 1,2,3,5, 6,7, 8,9, 10,11, 13a,14,14a,l 5, 16, 16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxamide
Figure imgf000106_0001
A solution of the product of Example lh (tert-butyl (2R,6S,13aS,14aR,16aS,Z)-2-(3- fluorophenanthridin-6-yloxy)-14a-(l-methylcyclopropylsulfonylcarbamoyl)-5,16-dioxo- 1,2,3,5,6,7,8,9,10,11,13a, 14,14a, 15,16, 16a-hexadecahydrocyclopropa[e]pyrrolo[l, 2- a][l,4]diazacyclopentadecin-6-ylcarbamate, 16.0 g, 20.6 mmol) in dichloromethane (100 mL) and 4 N HC1 in dioxane (100 mL) was stirred at room temperature for 90 min and then evaporated under reduced pressure. The residue was partitioned between ethyl acetate (200 mL) and saturated aqueous sodium bicarbonate solution (200 mL) and the resulting solid isolated by filtration of the mixture through a medium porosity sintered glass funnel. The isolated solid was washed with water (2 x 150 mL) and dried under reduced pressure to provide the title compound (12.2 g, 88% yield).
Example 1 (Route 2). N-((2R,6S,13aS,14aR,16aS,Z)-2-(3-fluorophenanthridin-6-yloxy)-14a- (l-methylcyclopropylsulfonylcarbamoyl)-5,16-dioxo- 1,2,3,5, 6,7, 8,9, 10,11, 13a,14,14a,15, 16, 16a-hexadecahydrocyclopropa[e]pyrrolo[l, 2- a][l,4]diazacyclopentadecin-6-yl)-5-methylisoxazole-3-carboxamide
A solution of the product of Example li ((2R,6S,13aS,14aR,16aS,Z)-6-amino-2-(3- fluorophenanthridin-6-yloxy)-N-(l-methylcyclopropylsulfonyl)-5,16-dioxo- 1,2,3,5, 6,7, 8,9, 10,11, 13a,14,14a,15, 16, 16a-hexadecahydrocyclopropa[e]pyrrolo[l, 2- a][l,4]diazacyclopentadecine-14a-carboxamide, 2.0 g, 3.0 mmol) and 5-methylisoxazole-3- carboxylic acid (0.38 g, 3.0 mmol) in dimethylformamide (30 mL) was cooled to 0 Β°C. To this mixture was added N-methylmorpholine (0.90 g, 8.9 mmol) followed by HATU (1.46 g, 3.84 mmol). The reaction mixture was stirred at to 0 Β°C for 30 min. To this mixture was added 1 N HCl (15 mL) followed by ethyl acetate (250 mL). The organic layer was washed with water and then saturated aqueous sodium chloride solution, separated, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with a gradient of acetone/hexane (1 :3 to 1 :2) to provide the title compound (1.9 g, 88% yield) as a white solid. MS(ESI): m/z = 787.0 [M+H]+.
Example lg, Route 3 (displacement of chlorophenanthridine by hydroxy acid)
Figure imgf000107_0001
Example lj. 6-chloro-3-fluorophenanthridine
Figure imgf000107_0002
To a mixture of 3-fluorophenanthridin-6-ol (Example la, 1.58 g, 7.41 mmol) in phosphorus oxychloride (11.7 g, 7.1 mL, 76 mmol) was added dimethylformamide (0.34 g, 0.46 mmol), and the reaction mixture was warmed to 65 Β°C and stirred under nitrogen for 1 h. The reaction mixture was cooled to room temperature, followed by the careful addition of ice to the reaction mixture. The mixture was stirred for 20 min, and the extracted with ethyl acetate. The resulting organic layer was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, filtered, and evaporated to provide the title compound (1.2 g, 70% yield), which was used without further purification.
Figure imgf000108_0001
1 k
i g
Example lg, (Route 3). (2R,6S,13aS,14aR,16aS,Z)-6-(tert-butoxycarbonylamino)-2-(3- f uorophenanthridin-6-yloxy)-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylic acid A mixture of (2R,6S,13aS,14aR,16aS,Z)-6-(tert-butoxycarbonylamino)-2-hydroxy-5,16- dioxo-1, 2,3,5,6,7,8,9,10,1 l,13a,14,14a,15, 16,16a-hexadecahydrocyclopropa[e]pyrrolo[l, 2- a][l,4]diazacyclopentadecine-14a-carboxylic acid (lk, 3.00 g, 6.44 mmol), 6-chloro-3- fluorophenanthridine (lj, 1.64 g, 7.09 mmol) and sodium 2-methylbutan-2-olate (2.84 g, 25.8 mmol) in dimethylformamide (21 mL) was stirred at room temperature for 2 h. An additional aliquot of sodium 2-methylbutan-2-olate (0.24 g, 2.8 mmol) was added and the reaction mixture was stirred for 1 h at room temperature. The reaction mixture was diluted with ethyl acetate and washed with 1 N HCl. The resulting aqueous phase was extracted with ethyl acetate, and the combined organic layer was washed with water followed by saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous magnesium sulfate, filtered, and evaporated under reduced pressure. The resulting residue was purified by flash chromatography on silica gel, eluting first with chloroform followed by a chloroform/methanol/acetic acid gradient (98:2:0.2 to 95:5:0.2) to provide the title compound (3.3 g, 78 % yield). This material was identical to the product of Example lg prepared according to Route 2.
Example 2.
N-((2R,6S,13aS,14aR,16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-2-(8- fluorophenanthridin-6-yloxy)-5,16-dioxo-l,2,3,5,6,7,8,9,10,ll,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecin-6-yl)-5- methylisoxazole-3-carboxamide.
Figure imgf000109_0001
Figure imgf000109_0002
Example 2a. 8-fluorophenanthridin-6-ol.
Figure imgf000109_0003
A mixture of methyl 2-bromo-5-fluorobenzoate (0.250 g, 1.07 mmol), 2-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)aniline (0.235 g, 1.07 mmol), palladium acetate (2.4 mg, 0.01 eq.), dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (8.81 mg, 0.021 mmol), and sodium carbonate (0.114 g, 1.073 mmol) in ethanol (5.4 mL) was heated to 80 Β°C for 3 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The resulting residue was triturated with hexane, and isolated by vacuum filtration, washed with water, and dried to provide the title compound (0.15 g, 65% yield) which was used without further purification. Example 2b. 6-chloro-8-fluorophenanthridine
Figure imgf000110_0001
To a mixture of 8-fluorophenanthridin-6-ol (Example 2a, 0.15 g, 0.69 mmol) in phosphorus oxychloride (1.06 g, 0.65 mL, 6.9 mmol) was added dimethylformamide (5 mg, 5 ΞΌΞ―), and the reaction mixture was warmed to 80 Β°C and stirred under nitrogen for 3 h. The reaction mixture was cooled to room temperature and evaporated under reduced pressure. The residue was triturated with hexane, and the resulting solid isolated by vacuum filtration, washed with water, and dried to provide the title compound (0.15 g, 95% yield) which was used without additional purification. Example 2d. tert-butyl (2R,6S,13aS,14aR,16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-2- (8-fluorophenanthridin-6-yloxy)-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecin-6-ylcarbamate
Figure imgf000110_0002
A mixture of tert-butyl (2R,6S,13aS,14aR,16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-2- hydroxy-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecin-6-ylcarbamate (2c, 0.376 g, 0.660 mmol), 6-chloro-8-fluorophenanthridine (2b, 0.153 g, 0.660 mmol) and sodium 2-methylbutan-2-olate (0.218 g, 1.981 mmol) in dimethylformamide (6.6 mL) was stirred at room temperature for 2 h. The reaction mixture was added dropwise to 2N HCl (200 mL) and the resulting solid was collected by vacuum filtration, rinsed with water, and dried. The solid was purified by flash chromatography on silica gel, eluting with acetone/hexane, to provide the title compound (0.355 g, 70% yield) as a white solid.
Example 2e. (2R,6S,13aS,14aR,16aS,Z)-6-amino-N-(cyclopropylsulfonyl)-2-(8- fluorophenanthridin-6-yloxy)-5,16-dioxo- 1,2,3,5, 6,7, 8,9, 10,11, 13a,14, 14a, 15, 16, 16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxamide h drochloride
Figure imgf000111_0001
2d
2c
Example 2. N-((2R,6S,13aS,14aR,16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-2-(8- fluorophenanthridin-6-yloxy)-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecin-6-yl)-5- methylisoxazole-3-carboxamide
Figure imgf000111_0002
The title compound was prepared according to the procedure utilized for the preparation of Example 1, route 2, replacing the product of Example li with the product of Example 2e. The product was purified by flash chromatography on silica gel eluting with a gradient of acetone/hexane to provide the title compound (17.5 mg, 50% yield) as a white solid.
MS(ESI): m/z = 774.0 [M+H]+.
Synthesis of the cyclic peptide precursor
Figure imgf000112_0001
To a solution of Boc-L-2-amino-8-nonenoic acid 42a (1.36g, 5 mol) and the commercially available cis-L-hydroxyproline methyl ester 42b (1.09g, 6 mmol) in 15 ml DMF, was added DIEA (4 ml, 4eq.) and HATU (4g, 2eq). The coupling was carried out at 0 Β°C over a period of 1 hour. The reaction mixture was diluted with 100 mL EtOAc, and followed by washing with 5% citric acid 2x 20 ml, water 2x20 ml, 1M NaHC03 4x20 ml and brine 2x10 ml, respectively. The organic phase was dried over anhydrous Na2S04 and then was evaporated, affording the dipeptide 42c (1.91g, 95.8%) that was identified by HPLC (Retention time = 8.9 min, 30-70%, 90%B), and MS (found 421.37, M+Na+).
The dipeptide 42c (1.91g) was dissolved in 15 mL of dioxane and 15 mL of 1 N LiOH aqueous solution and the hydrolysis reaction was carried out at room temperature for 4 hours. The reaction mixture was acidified by 5% citric acid and extracted with 100 mL
EtOAc, and followed by washing with water 2x20 ml, and brine 2x20 ml, respectively. The organic phase was dried over anhydrous Na2S04 and then removed in vacuum, yielding the free carboxylic acid compound 42d (1.79g, 97%), which was used for next step synthesis without need for further purification.
To a solution of the free acid obtained above (1.77, 4.64 mmol) in 5 ml DMF, D-Ξ²- vinyl cyclopropane amino acid ethyl ester (0.95g, 5 mmol), DIEA (4 ml, 4eq.) and HATU (4g, 2eq) were added. The coupling was carried out at 0 Β°C over a period of 5 hours. The reaction mixture was diluted with 80 mL EtOAc, and followed by washing with 5% citric acid 2x 20 ml, water 2x20 ml, 1M NaHC03 4x20 ml and brine 2x10 ml, respectively. The organic phase was dried over anhydrous Na2S04 and then evaporated. The residue was purified by silica gel flash chromatography using different ratios of hexanes: EtOAc as elution phase (5:1β€” >3:1β€” >1:1β€” >1:2β€” >1:5). The linear tripeptide 42e was isolated as an oil after removal of the elution solvents (1.59g, 65.4%), identified by HPLC (Retention time = 11.43 min) and MS (found 544.84, M+Na+).
A solution of the linear tripeptide 42e (1.51g, 2.89 mmol) in 200 ml dry DCM was deoxygenated by bubbling N2. Hoveyda's 1st generation catalyst (5 mol% eq.) was then added as solid. The reaction was refluxed under N2 atmosphere 12 hours. The solvent was evaporated and the residue was purified by silica gel flash chromatography using different ratios of hexanes :EtO Ac as elution phase (9:1β€” >5:1β€” >3:1β€” >1:1β€” >1:2β€” >1:5). The cyclic peptide precursor was isolated as a white powder after removal of the elution solvents (1.24g, 87%), identified by HPLC (Retention time = 7.84 min, 30-70%, 90%B), and MS (found 516.28, M+Na+).
(2S,6S,13aS,14aR,16aS,Z)-ethyl 2-(4-bromophenylsulfonyloxy)-6-(tert- butoxycarbonylamino)-5,16-dioxo-l,2,3,5,6,7,8,9,10,ll,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylate
Figure imgf000114_0001
1 a
A solution of (2S,6S,13aS,14aR,16aS,Z)-ethyl 6-(tert-butoxycarbonylamino)-2- hydroxy-5,16-dioxo-l,2,3,5,6,7,8,9,10,l l,13a,14,14a,15,16,16a- hexadecahydrocyclopropa[e]pyrrolo[l,2-a][l,4]diazacyclopentadecine-14a-carboxylate (22.1 g, 44.8 mmol) and DABCO (8.5 g, 76.7 mmol) in toluene (88 mL) was stirred at room temperature. To this solution was added a solution of 4-bromobenzene-l-sulfonyl chloride 17.2 g, 67.2 mmol) in toluene (44 mL). After the addition was complete the reaction mixture was quenched with 10% aqueous sodium carbonate (110 mL) and the mixture stirred for 15 min. Tetrahydrofuran (44 mL) was added and the mixture was washed with 0.5 M HC1, water, and then saturated aqueous sodium chloride. The organic layer was dried over anhydrous magnesium sulfate, filtered, and evaporated under reduced pressure and dried to provide the title compound (27.7 g, 87% yield), which was used without further purification.
Example 4
Measurement of potency of inhibition with purified NS3 protease enzyme
The activity of recombinant HCV NS3 proteases derived from isolates representing genotypes 1, 2, 3 or 4 is measured by cleavage of the following peptide substrate: H2
Figure imgf000114_0002
The substrate is labeled with a fluor and a fluorescence quencher. Cleavage results in release of the quencher and an increase in fluorescence. NS3 protease is incubated with a dilution series of inhibitor in 150 mM NaCl, 10% Glycerol, 5 mM DTT, with or without 0.01% dodecyl maltoside for either 30 minutes or 300 minutes. Substrate is added at a concentration of 5 uM to initiate the reaction, and fluorescence is measured at 2 minute intervals for 30 minutes. Enzyme concentrations range from 10 to 100 nM in the absence of detergent, or 10-fold lower in the presence of detergent. Substrate peptides are labeled with either EDANS and DABCYL (excitation 355 nm, emission 485 nm) or TAMRA and QSY (excitation 544 nm, emission 590 nm). For routine IC50 determination, 3-fold serial dilutions starting with initial concentrations of 100 μΜ, 200 μΜ, or 2 mM are used. For compounds with Kj values approaching or lower than the enzyme concentration, a tight-binding calculation format is used, with 24 dilutions of inhibitor covering a range of 0 to 100 nM inhibitor. K; values are calculated using the tight binding assay format, according to the following equation:
V = A{ [(K + I - E)2 + 4KE])1/2 - (K + I - E)}, where I = total inhibitor concentration, E = active enzyme concentration, K = apparent Kj value and A = [kcat)S/2] [Km = (S)].
Replicon cell lines
Two subgenomic replicon cell lines can be used for compound characterization in cell culture: one derived from genotype la and one derived from genotype lb. Both replicon constructs are bicistronic subgenomic replicons essentially similar to those described by Bartenschlager and coworkers (Lohmann et al., Science (1999) 285(5424):110-113). The genotype la replicon construct contains the NS3-NS5B coding region derived from the H77 strain of HCV (la-H77) (Blight et al., J Virol (2003) 77(5):3181-3190). The first cistron of the construct consists of the first 36 nucleotides of the HCV la-H77 core gene fused to a firefly luciferase reporter and a neomycin phosphotransferase (Neo) selectable marker. The luciferase and Neo coding regions are separated by the FMDV 2a protease. The second cistron contains the NS3-NS5B coding region derived from la-H77 with the addition of adaptive mutations E1202G in NS3, K1691R in NS4A, and K2040R and S2204I in NS5A. The lb-Con- 1 replicon construct is identical to the la-H77 replicon, except that the 5' and 3' NTRs and the NS3-NS5B coding region can be derived from the lb-Con- 1 strain (Blight et al., Science (2000) 290(5498):1972-1974), and the adaptive mutations are E1202G and T1280I in NS3 and S2204I in NS5A.
Replicon compound testing
Replicon cell lines can be maintained in Dulbecco's modified Eagles medium
(DMEM) containing 100 IU/ml penicillin, 100 mg/ml streptomycin (Invitrogen), 200 mg/ml G418 (Invitrogen) and 10% (v/v) fetal bovine serum (FBS). Replicon-containing cells can be seeded into 96 well plates at a density of 5000 cells per well in 100 μΐ DMEM containing 5% FBS. The next day, the compound can be initially diluted in dimethyl sulfoxide (DMSO) to generate a 200x stock of the inhibitor in a series of 8 half-log dilutions. The dilution series can then be diluted 100-fold in the medium containing 5% FBS. One hundred microliters of medium with the inhibitor can be added to each well of the overnight cell culture plate already containing 100 μΐ of DMEM with 5% FBS. In assays where the protein binding effect on inhibitor potency is assessed, the medium from the overnight cell culture plates can be replaced with 200 μΐ DMEM containing 40% human plasma (Innovative Research) plus 5% FBS as well as compound. The cells can be grown for 4 days in tissue culture incubators. The inhibitory effects of compounds against the replicons can be determined by measuring either the level of luciferase or HCV RNA. The luciferase assay can be conducted using a Luciferase Assay System kit (Promega) following the manufacturer's instructions. Briefly, the cell culture medium is removed and wells are washed with 200 μΐ of phosphate-buffered saline. To each well Passive Lysis buffer (Promega, WI) is added and the plates are incubated for 30 min with rocking to lyse the cells. Luciferin solution (50 μΐ, Promega) is added, and luciferase activity is measured with a Victor II luminometer (Perkin-Elmer). To determine HCV RNA levels, RNA extractions can be performed using the CellsDirect kit (Invitrogen), and the HCV RNA copy number can be measured using the Superscript III Platinum One- Step qRT-PCR system (Invitrogen) and primers specific to the HCV 5' nontranslated region. Cytotoxicity can be determined by the 3-[4,5-dimethythiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay as follows. Replicon cells is plated in 96- well plates
(4000 cells per well), the next day compound dilutions are added as in the activity assay, and the cells are grown in the presence of the inhibitors for 4 days. The MTT solution is diluted in DMEM containing 5% FBS and 60 μΐ of the solution is added to the cells. After 4 hrs, the cells are solubilized by the addition of 30 μΐ SDS (20% in 0.02 N HC1). The plates are incubated overnight and the optical density can be measured at 570nm. To determine compounds' EC50 and TD50, luciferase, RNA inhibition and MTT data can be analyzed using the GraphPad Prism 4 software (equation: sigmoidal dose-response - variable slope).
Mutants in transient replicons
Mutations detected in resistance selection studies can be introduced into wild type transient replicon constructs based on genotypes la-H77 and lb-N. Both replicons are bicistronic sub-genomic constructs containing a firefly luciferase reporter similar to those described above, but they do not contain a Neo selectable marker and are therefore only suitable for transient replication assays. The la-H77 replicon for transient assays further differs from the replicon in the stable cell line in that it contains NS2 through NS5B in the second cistron. The lb-N strain replicon contains NS3 through NS5B in the second cistron, with adaptive mutations E1202G in NS3 and S2204I in NS5A. Mutagenesis can be performed using the Stratagene QuikChange XL II site-directed mutagenesis kit. Mutants' sequences can be confirmed, plasmids can be linearized with Xba I restriction enzyme and used as template for in vitro transcription reactions to make mutant replicon RNA for transient transfections. In vitro transcription can be performed with the T7 Megascript kit (Ambion).
Transient replicon transfections can be performed essentially as described by Mo et al. (Antimicrob Agents Chemother (2005) 49(10):4305-4314) with slight modifications. Fifteen micrograms of template RNA can be used to electroporate 3xl06 cells in a 200 μΐ volume in a 0.2 cm cuvette. The cells used for transient transfections can be Huh7 cells obtained by curing replicon-containing cells with IFN (Mo et al., supra). Electroporation can be done with a Gene Pulser II (Bio-Rad, CA) at 480V and 25μΑ, using two manual pulses.
Transfected cells can be diluted to 7.5x10 4 cells/ml and plated in 96 well plates at 7.5x103 cells per well in DMEM with 5% FBS and 100 IU/ml penicillin, 100 mg/ml streptomycin (Invitrogen). Four hours post-transfection, one plate is harvested for luciferase measurement; this plate may provide a measure of the amount of input RNA that can be translated, and thus of transfection efficiency. To the remaining plates, test compound serial dilutions in DMSO can be added (0.5% DMSO final concentration), and plates are incubated for 4 days.
Exemplary compounds of the present invention were tested for their anti-HCV activities. Many of the compounds tested showed unexpected anti-HCV activities, including excellent activities in biochemical assays against HCV proteases representing various HCV genotypes, superior activities in standard HCV replicon assays including activity against la- H77 and lb-conl HCV strains in the absence or presence of 40% human plasma, and/or excellent activities in transient replicon assays against drug-resistant mutants in a number of different HCV genetic backgrounds.
The contents of all references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated herein in their entireties by reference. Unless otherwise defined, all technical and scientific terms used herein are accorded the meaning commonly known to one with ordinary skill in the art. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended with be encompassed by the following claims.

Claims

WHAT IS CLAIMED:
1. A compound of formula I:
Figure imgf000119_0001
( I )
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein:
J is absent, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, -C(O)-, -O-C(O)-, - N(R3)-C(0)-, -C(S)-, -C(=NR4)-, - S(0)-, -S(02)-, or -N(R3)-;
A is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted carbocyclic;
each Ri is independently selected from
(i) halogen, hydroxy, amino, -CN, -CF3, -N3, -N02, -OR4, -SR4, -SOR4, -SO^, -N(R3)S(0)2-R4, -N(R3)(S02)NR3R4, -NR3R4, -C(0)-0_R4, -C(0)R4, - C(0)NR3R4, or -N(R3)C(0)R4;
(ii) optionally substituted aryl;
(iii) optionally substituted heteroaryl;
(iv) optionally substituted heterocyclic;
(v) optionally substituted carbocyclic; or
(vi) optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; wherein at least one of Ri is halogen or -OR4;
G is -E-R5;
wherein E is absent; optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; or -0-, -S-, -N(R3)-, -N(R3)S(Op)-, -N(R3)C(0)-, -N(R3)
C(0)S(Op)-, -OS(Op)-, -C(0)S(Op)-, or -C(0)N(R3)S(Op)-;
each p is independently 0, 1, or 2;
R5 is H; optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl;
R3 and R4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen;
L is absent or is selected from optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
j = 0, 1, 2, 3, or 4;
k= 0, 1, 2, or 3;
m = 0, 1, or 2;
n is 1, 2, 3, or 4; and
or double bond
Figure imgf000120_0001
2. The compound of claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein E is -NHS(O)- or -NHS(02)-, and R5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, or imidazolyl, each of which is optionally substituted.
3. The compound of claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein J is -C(O)- and A is optionally substituted -Q-Q alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, optionally substituted -Ci-C8 alkoxy, optionally substituted heteroaryl, optionally substituted -C3-C12 cycloalkyl, or optionally substituted -C3-Ci2 heterocycloalkyl. 4. The compound of claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein each Ri is independently selected from halogen, hydroxy, amino, -CN, -CF3, -N3, -NO2, -OR4, -SR4, -SOR4, -SO2R4, -N(R3)S(02) -R4, -N(R3) S(02)NR3R4, -NR3R4, - C(0)OR4, -C(0)R4, -C(0)NR3R4, or -N(R3)C(0)R4; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; wherein at least one Ri is halogen or -OR4-.
5. The compound of claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein each Ri is independently halogen or -OR4.
6. The compound of claim 1, or a pharmaceutically acceptable salt, ester or prodrug
thereof, wherein
Figure imgf000121_0001
from the following:
Figure imgf000121_0002
Figure imgf000122_0001
7. The compound of claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein k=3, j=l and L is absent.
The compound of claim 1, of formula II,
Figure imgf000123_0001
( Ξ  )
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein:
J is absent, -C(O)-, - N(R3)-C(0)-, -C(S)-, -C(=NR4)-, -S(O)-, -S(02)-, or -N(R3)-; A is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted carbocyclic;
each Ri is independently selected from
(i) halogen, hydroxy, amino, -OR4, -N(R3)S(0)2-R4, -N(R3)(S02)NR3R4, -
NR3R4, -C(0)-0-R4, -C(0)R4, -C(0)NR3R4, or -N(R3)C(0)R4;
(Ο‹) optionally substituted aryl;
(iii) optionally substituted heteroaryl;
(iv) optionally substituted heterocyclic;
(v) optionally substituted carbocyclic; or
(vi) optionally substituted alkyl, optionally substituted alkenyl, or optionally
substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from 0,
S, or N;
wherein at least one of Ri is halogen or -OR4-;
R5 is H; optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl; R3 and R4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen;
n is 1, 2, 3, or 4; and
Figure imgf000124_0001
===== enotes a car on-car on s ng e on ΒΎ ) or double bond
Figure imgf000124_0002
9. The compound of claim 8, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein R5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, or imidazolyl, each of which is optionally substituted.
10. The compound of claim 8, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein J is -C(O)- and A is optionally substituted -Ci-C8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, optionally substituted -Ci-C8 alkoxy, optionally substituted heteroaryl, optionally substituted -C3-C12 cycloalkyl, or optionally substituted -C3-Ci2 heterocycloalkyl.
11. The compound of claim 8, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is selected from Me, i-Pr, -Bu, t-Bu,
Figure imgf000124_0003
Figure imgf000125_0001
12. The compound of claim 8, or a pharmaceutically acceptable salt, ester or prodrug
Figure imgf000125_0002
-NHC(O)-, -NHC(0)0-, -C(O)-, -O-C(O)-, -C(S)-, -S(O)-,
A' is optionally substituted -Ci-C8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted -Ci-C8 haloalkyl, optionally substituted aryl, optionally substituted -Ci-C8 alkoxy, optionally substituted heteroaryl, optionally substituted -C3-C12 cycloalkyl, or optionally substituted -C3-Ci2 heterocyclyl;
R' is H, optionally substituted -Ci-C8 alkyl, optionally substituted -C3-C12 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted -C3-C12 heterocyclyl;
R" is H, optionally substituted -Ci-C8 alkyl, optionally substituted -C3-C12 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted -C3-C12 heterocyclyl; and
t is 0 or 1.
13. The compound of claim 12, wherein J' is -NHC(O)-, or -NHC(0)0-; A' is optionally substituted -Ci-C8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, or optionally substituted heteroaryl; R' is H, optionally substituted -Ci-C8 alkyl or optionally substituted -C3-C12 cycloalkyl; R" is H, and t is 0 or 1.
14. The compound of claim 13, wherein A' is Me, Et, Pr, i-Pr, Bu, s-Bu, t-Bu, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, imidazolyl,
Figure imgf000126_0001
each of which is optionally substituted.
15. The compound of claim 8, wherein A is
Figure imgf000126_0002
wherein,
J" is -NC(O)-, -NC(0)0-, -C(O)-, -O-C(O)-, -C(S)-, -C(=NR4)-, -S(O)-, -S(02)-; and A" is optionally substituted -Ci-C8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted -Ci-C8 haloalkyl, optionally substituted aryl, optionally substituted -Ci-C8 alkoxy, optionally substituted heteroaryl, optionally substituted -C3-Ci2 cycloalkyl, or optionally substituted -C3-Ci2 heterocyclyl. 16. The compound of claim 8, wherein A is -CHRz(OH)-, wherein Rz is cyclohexyl, i-Pr, i-Bu, t-Bu, or CF3.
17. The compound of claim 8, wherein, A is CHF2-Ry, wherein Ry is Ph or Et.
18. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt, ester, or prodrug thereof, in combination with a pharmaceutically acceptable carrier or excipient.
19. A method of treating a viral infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt, ester or prodrug thereof.
20. A method of producing a compound of formula I, or a pharmaceutically acceptable salt, ester or prodrug thereof, comprising the step of reacting a compound of formula X:
Figure imgf000127_0001
(X);
wherein,
J is absent, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, -C(O)-, -O-C(O)-, - N(R3)-C(0)-, -C(S)-, -C(=NR4)-, - S(0)-, -S(02)-, or -N(R3)-;
A is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted carbocyclic;
G is -E-R5;
wherein E is absent; optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; or -0-, -S-, -N(R3)-, -N(R3)S(Op)-, -N(R3)C(0)-, -N(R3)
C(0)S(Op)-, -OS(Op)-, -C(0)S(Op)-, or -C(0)N(R3)S(Op)-; each p is independently 0, 1, or 2;
R5 is H; optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl;
R3 and R4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen;
L is absent or is selected from optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
j = 0, 1, 2, 3, or 4;
k= 0, 1, 2, or 3;
= 0, 1, or 2;
Figure imgf000128_0001
es a carbon-carbon single bond ( ) or double bond
Figure imgf000128_0002
LG is a leaving group;
with a compound of formul
Figure imgf000128_0003
wherein:
each Ri is independently selected from
(i) halogen, hydroxy, amino, -CN, -CF3, -N3, -N02, -OR4, -SR4, -SOR4, -SO^,
-N(R3)S(0)2-R4, -N(R3)(S02)NR3R4, -NR^, -C(0)-0_R4, -C(0)R4, -
C(0)NR3R4, or -N(R3)C(0)R4; (ii) optionally substituted aryl;
(iii) optionally substituted heteroaryl;
(iv) optionally substituted heterocyclic;
(v) optionally substituted carbocyclic; or
(vi) optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; wherein at least one of Ri is halogen or -OR4-; and
n is 1, 2, 3, or 4;
to thereby produce a compound of formula I.
PCT/US2011/067701 2010-12-30 2011-12-29 Phenanthridine macrocyclic hepatitis c serine protease inhibitors WO2012092411A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2013007698A MX2013007698A (en) 2010-12-30 2011-12-29 Phenanthridine macrocyclic hepatitis c serine protease inhibitors.
SG2013049416A SG191759A1 (en) 2010-12-30 2011-12-29 Phenanthridine macrocyclic hepatitis c serine protease inhibitors
AU2011352145A AU2011352145A1 (en) 2010-12-30 2011-12-29 Phenanthridine macrocyclic hepatitis C serine protease inhibitors
CA2821340A CA2821340A1 (en) 2010-12-30 2011-12-29 Phenanthridine macrocyclic hepatitis c serine protease inhibitors
BR112013016480A BR112013016480A2 (en) 2010-12-30 2011-12-29 phenanthridine macrocycle hepatitis c serine protease inhibitors
CN201180068287.6A CN103380132B (en) 2010-12-30 2011-12-29 Phenanthridines macrocyclic hepatitis C serine protease inhibitors
KR1020137020148A KR20140003521A (en) 2010-12-30 2011-12-29 Phenanthridine macrocyclic hepatitis c serine protease inhibitors
EP11853433.8A EP2658858A4 (en) 2010-12-30 2011-12-29 Phenanthridine macrocyclic hepatitis c serine protease inhibitors
EA201390988A EA201390988A1 (en) 2010-12-30 2011-12-29 PHENANTRIDINE MACROCYCLIC INHIBITORS OF THE HYPATITIS C VIRUS SERIN PROTEASE
JP2013547656A JP2014506255A (en) 2010-12-30 2011-12-29 Phenanthridine macrocyclic hepatitis C serine protease inhibitor
ZA2013/04579A ZA201304579B (en) 2010-12-30 2013-06-20 Phenanthridine macrocyclic hepatitis c serine protesea inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201061428488P 2010-12-30 2010-12-30
US61/428,488 2010-12-30
US201161449331P 2011-03-04 2011-03-04
US61/449,331 2011-03-04

Publications (2)

Publication Number Publication Date
WO2012092411A2 true WO2012092411A2 (en) 2012-07-05
WO2012092411A3 WO2012092411A3 (en) 2012-11-08

Family

ID=46383854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/067701 WO2012092411A2 (en) 2010-12-30 2011-12-29 Phenanthridine macrocyclic hepatitis c serine protease inhibitors

Country Status (18)

Country Link
US (1) US8951964B2 (en)
EP (1) EP2658858A4 (en)
JP (1) JP2014506255A (en)
KR (1) KR20140003521A (en)
CN (1) CN103380132B (en)
AU (1) AU2011352145A1 (en)
BR (1) BR112013016480A2 (en)
CA (1) CA2821340A1 (en)
CO (1) CO6771427A2 (en)
CR (1) CR20130341A (en)
EA (1) EA201390988A1 (en)
EC (1) ECSP13012791A (en)
GT (1) GT201300172A (en)
MX (1) MX2013007698A (en)
PE (1) PE20140039A1 (en)
SG (1) SG191759A1 (en)
WO (1) WO2012092411A2 (en)
ZA (1) ZA201304579B (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2015038596A1 (en) 2013-09-11 2015-03-19 Emory University Nucleotide and nucleoside compositions and uses related thereto
US9296782B2 (en) 2012-07-03 2016-03-29 Gilead Sciences, Inc. Inhibitors of hepatitis C virus
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9499550B2 (en) 2012-10-19 2016-11-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9617310B2 (en) 2013-03-15 2017-04-11 Gilead Sciences, Inc. Inhibitors of hepatitis C virus
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11820751B2 (en) 2021-01-27 2023-11-21 Vandria Sa Urolithin derivatives and methods of use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Family Cites Families (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831002A (en) 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
ES2241157T3 (en) 1997-08-11 2005-10-16 Boehringer Ingelheim (Canada) Ltd. INHIBITING PEPTIDES OF HEPATITIS C.
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
AR022061A1 (en) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd INHIBITING PEPTIDES OF HEPATITIS C, A PHARMACEUTICAL COMPOSITION CONTAINING THEM, THE USE OF THE SAME TO PREPARE A PHARMACEUTICAL COMPOSITION, THE USE OF AN INTERMEDIATE PRODUCT FOR THE PREPARATION OF THESE PEPTIDES AND A PROCEDURE FOR THE PREPARATION OF ANOGRAPH .
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
CA2390349A1 (en) 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
EP1261611A2 (en) 2000-02-29 2002-12-04 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
EP1337550B1 (en) 2000-11-20 2006-05-24 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
AU2002230764A1 (en) 2000-12-13 2002-06-24 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
FR2821272B1 (en) 2001-02-23 2004-12-17 Synt Em COMPOUNDS CONSISTING OF AN ANALGESIC MOLECULE LINKED TO A VECTOR CAPABLE OF VECTORIZING THE SAME MOLECULATED THROUGH THE HEMATOENCEPHALIC BARRIER AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2003025563A1 (en) 2001-09-16 2003-03-27 Chemometec A/S Method and a system for detecting and optionally isolating a rare event particle
WO2003026587A2 (en) 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
AU2003301959A1 (en) 2002-05-20 2004-06-03 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
US20060199773A1 (en) 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003299519A1 (en) 2002-05-20 2004-05-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2003099316A1 (en) 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
US20030232386A1 (en) 2002-06-17 2003-12-18 Shah Dinesh O. Assay conjugate and uses thereof
WO2004002405A2 (en) 2002-06-26 2004-01-08 Bristol-Myers Squibb Company Amino-bicyclic pyrazinones and pyridinones
AU2003261434A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
US20040138109A1 (en) 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US20050159345A1 (en) 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
JP2007524576A (en) 2003-02-07 2007-08-30 γ‚¨γƒŠγƒ³γ‚Ώ γƒ•γ‚‘γƒΌγƒžγ‚·γƒ₯ーティカルズ むンコーポレむテッド Macrocyclic hepatitis C serine protease inhibitor
WO2004101605A1 (en) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
UY28240A1 (en) 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma CRYSTAL PHASES OF A POWERFUL HCV INHIBITOR
JP2006522017A (en) 2003-04-02 2006-09-28 ベーγƒͺンガー むンゲルハむム γ‚€γƒ³γ‚ΏγƒΌγƒŠγ‚·γƒ§γƒŠγƒ« γ‚²γ‚Όγƒ«γ‚·γƒ£γƒ•γƒˆ γƒŸγƒƒγƒˆ ベシγƒ₯レンクテル ハフツング Pharmaceutical composition for hepatitis C virus protease inhibitor
US7148347B2 (en) 2003-04-10 2006-12-12 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
CN1771257A (en) 2003-04-10 2006-05-10 θ΄ζž—ζ Όε°”Β·θ‹±ζ Όζ΅·ε§†ε›½ι™…ζœ‰ι™ε…¬εΈ Process for the preparation of macrocyclic compounds by ruthenium complex catalysed metathesis reaction
US7173004B2 (en) 2003-04-16 2007-02-06 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
CA2522561C (en) 2003-04-18 2012-07-17 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
UY28323A1 (en) 2003-05-21 2004-12-31 Boehringer Ingelheim Int INHIBITING COMPOUNDS OF HEPATITIS C
US7273851B2 (en) 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
US7112601B2 (en) 2003-09-11 2006-09-26 Bristol-Myers Squibb Company Cycloalkyl heterocycles for treating hepatitis C virus
PE20050431A1 (en) 2003-09-22 2005-07-19 Boehringer Ingelheim Int MACROCYCLIC PEPTIDES ACTIVE AGAINST HEPATITIS C VIRUS
BRPI0414814A (en) 2003-09-26 2006-11-14 Schering Corp macrocyclic hepatitis c virus serine ns3 protease inhibitors
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
NZ546347A (en) 2003-10-14 2009-11-27 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2546290A1 (en) 2003-11-20 2005-06-09 Schering Corporation Depeptidized inhibitors of hepatitis c virus ns3 protease
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
FR2863268B1 (en) 2003-12-09 2006-02-24 Sod Conseils Rech Applic NOVEL DERIVATIVES OF 2-HYDROXYTETRAHYDROFURAN AND THEIR APPLICATION AS MEDICAMENTS
WO2005058821A1 (en) 2003-12-11 2005-06-30 Schering Corporation Inhibitors of hepatitis c virus ns3/ns4a serine protease
ES2358333T3 (en) 2004-01-21 2011-05-09 Boehringer Ingelheim International Gmbh MACROCYCLIC PEPTIDES WITH ACTION AGAINST THE VIRUS OF HEPATITIS C.
JP4769200B2 (en) 2004-01-28 2011-09-07 ベーγƒͺンガー むンゲルハむム γ‚€γƒ³γ‚ΏγƒΌγƒŠγ‚·γƒ§γƒŠγƒ« γ‚²γ‚Όγƒ«γ‚·γƒ£γƒ•γƒˆ γƒŸγƒƒγƒˆ ベシγƒ₯レンクテル ハフツング Method for removing transition metals from reaction solutions containing transition metal byproducts
WO2005073195A2 (en) 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
CA2556917C (en) 2004-03-15 2013-07-09 Boehringer Ingelheim International, Gmbh Process for preparing macrocyclic compounds
CA2560897C (en) 2004-03-30 2012-06-12 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
JP5156374B2 (en) 2004-05-25 2013-03-06 ベーγƒͺンガー むンゲルハむム γ‚€γƒ³γ‚ΏγƒΌγƒŠγ‚·γƒ§γƒŠγƒ« γ‚²γ‚Όγƒ«γ‚·γƒ£γƒ•γƒˆ γƒŸγƒƒγƒˆ ベシγƒ₯レンクテル ハフツング Method for preparing acyclic HCV protease inhibitor
WO2006000085A1 (en) 2004-06-28 2006-01-05 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
DE102004033312A1 (en) 2004-07-08 2006-01-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Continuous metathesis process with ruthenium catalysts
NZ552405A (en) 2004-07-16 2011-04-29 Gilead Sciences Inc Pyrrolidine containing antiviral compounds
WO2006007708A1 (en) 2004-07-20 2006-01-26 Boehringer Engelheim International Gmbh Hepatitis c inhibitor peptide analogs
UY29016A1 (en) 2004-07-20 2006-02-24 Boehringer Ingelheim Int ANALOGS OF INHIBITING DIPEPTIDES OF HEPATITIS C
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7375218B2 (en) 2004-09-17 2008-05-20 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic HCV protease inhibitors
CA2578428A1 (en) 2004-09-17 2006-03-30 Boehringer Ingelheim International Gmbh Ring-closing metathesis process in supercritical fluid
ATE533473T1 (en) 2004-09-24 2011-12-15 Boehringer Ingelheim Pharma NEW CLASS OF SURFUCT-LIKE MATERIALS WITH VITAMIN E-TPGS AND WATER SOLUBLE POLYMER
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
EP1824816A4 (en) 2004-10-14 2008-01-02 Wuxi Pharma Tech Co Ltd A NOVEL PROCESS FOR THE PREPARATION OF NONRACEMIC LONG CHAIN alpha-AMINO ACIDS DERIVATIVES
WO2006043145A1 (en) 2004-10-21 2006-04-27 Pfizer Inc. Inhibitors of hepatitis c virus protease, and compositions and treatments using the same
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL1863833T3 (en) 2005-03-08 2014-03-31 Boehringer Ingelheim Int Process for preparing macrocyclic compounds
US20080188494A1 (en) 2005-04-25 2008-08-07 Basf Aktiengesellschaft Use Of 5-Alkyl-6-Phenylalkyl-7-Aminoazolopyrimidines, Novel Azolopyrimidines, Processes For Their Preparation And Compositions Comprising Them
CA2606195C (en) 2005-05-02 2015-03-31 Merck And Co., Inc. Hcv ns3 protease inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006128455A2 (en) 2005-05-25 2006-12-07 2Curex Aps Compounds modifying apoptosis
WO2006130687A2 (en) 2005-06-02 2006-12-07 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor
CA2611145A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation useful for treating disorders associated with hepatitis c virus
US20060275366A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
WO2006130627A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis c
WO2006130552A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
US20070004635A1 (en) 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
NZ563361A (en) 2005-06-02 2011-02-25 Schering Corp HCV protease inhibitors in combination with food
WO2006130554A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
US20060276404A1 (en) 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US20070237818A1 (en) 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
JP5160415B2 (en) 2005-06-02 2013-03-13 パルク・シャープ・をンド・ドーム・コーポレーション Pharmaceutical formulation and therapeutic method using the same
WO2006130626A2 (en) 2005-06-02 2006-12-07 Schering Corporation Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period
US20060287248A1 (en) 2005-06-02 2006-12-21 Schering Corporation Asymmetric dosing methods
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (en) 2005-07-14 2013-03-21 Gilead Sciences Inc Antiviral compounds
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
EP1910378B1 (en) 2005-07-20 2012-06-20 Boehringer Ingelheim International GmbH Hepatitis c inhibitor peptide analogs
US20090148407A1 (en) 2005-07-25 2009-06-11 Intermune, Inc. Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
PE20070211A1 (en) 2005-07-29 2007-05-12 Medivir Ab MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
MY139988A (en) 2005-07-29 2009-11-30 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
MY141245A (en) 2005-07-29 2010-03-31 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
JO2768B1 (en) 2005-07-29 2014-03-15 ΨͺيبوΨͺΩŠΩƒ ΩΨ§Ψ±Ω…Ψ§Ψ³ΩŠΩˆΨͺΩŠΩƒΨ§Ω„Ψ² Ω„ΩŠΩ…ΨͺΨ― Macrocylic Inhibitors Hepatitis C Virus
TW200745061A (en) 2005-07-29 2007-12-16 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis C virus
PE20070343A1 (en) 2005-07-29 2007-05-12 Medivir Ab MACRO CYCLIC INHIBITORS OF HEPATITIS C VIRUS
PL1913015T3 (en) 2005-07-29 2014-04-30 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis c virus
BRPI0614205A2 (en) 2005-08-01 2016-11-22 Merck & Co Inc compound, pharmaceutical composition and compound use
AR055395A1 (en) 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
ES2364426T3 (en) 2005-09-09 2011-09-02 Boehringer Ingelheim International Gmbh METAL PROCESS WITH CLOSURE OF THE RING FOR THE PREPARATION OF MACROCYCLIC PEPTIDES.
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
ATE493409T1 (en) 2005-10-11 2011-01-15 Intermune Inc COMPOUNDS AND METHODS FOR INHIBITING HEPATITIS C VIRUS REPLICATION
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
US20070287664A1 (en) 2006-03-23 2007-12-13 Schering Corporation Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
WO2007130592A2 (en) 2006-05-04 2007-11-15 Crawford Ted C Head cap for a wrench head, wrench and method utilizing the same
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US20070281884A1 (en) 2006-06-06 2007-12-06 Ying Sun Macrocyclic oximyl hepatitis C protease inhibitors
US8268776B2 (en) 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
UY30437A1 (en) * 2006-06-26 2008-01-31 Enanta Pharm Inc QUINOXALINIL MACROCECLIC INHIBITORS OF SERINE PROTEASE VIRUS OF HEPATITIS C
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
BRPI0714343A2 (en) 2006-07-13 2013-03-19 Achillion Pharmaceuticals Inc 4-amino-4-oxobutanoyl peptides as viral replication inhibitors
CA2656816A1 (en) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
WO2008019303A2 (en) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
US20090035271A1 (en) 2007-08-01 2009-02-05 Ying Sun Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
US7582605B2 (en) 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
WO2008021960A2 (en) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Triazolyl macrocyclic hepatitis c serine protease inhibitors
WO2008022006A2 (en) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis c virus protease inhibitors
US7687459B2 (en) 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US7605126B2 (en) 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US20080038225A1 (en) 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
AU2007300378A1 (en) 2006-09-27 2008-04-03 Coley Pharmaceutical Gmbh Compositions of TLR ligands and antivirals
EP2084182B1 (en) 2006-10-03 2013-08-28 Cadila Healthcare Limited Antidiabetic compounds
US20120220520A1 (en) 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment
WO2008051514A2 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
EP2079479B1 (en) 2006-10-24 2014-11-26 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
KR101615500B1 (en) 2006-10-27 2016-04-27 머크 샀프 μ•€λ“œ 돔 μ½”ν¬λ ˆμ΄μ…˜ HCV NS3 protease inhibitors
CA2667032A1 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
US20080107623A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US20080107625A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
TW200827364A (en) 2006-11-02 2008-07-01 Taigen Biotechnology Co Ltd HCV protease inhibitors
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA200970493A1 (en) 2006-11-17 2009-10-30 Π’ΠΈΠ±ΠΎΡ‚Π΅ΠΊ Π€Π°Ρ€ΠΌΠ°ΡΡŒΡŽΡ‚ΠΈΠΊΠ°Π»Π· Π›Ρ‚Π΄. MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS
WO2008070733A2 (en) 2006-12-06 2008-06-12 Phenomix Corporation Macrocyclic hepatitis c serine protease inhibitors and uses therefor
AU2008205116A1 (en) 2007-01-08 2008-07-17 Phenomix Corporation Macrocyclic hepatitis C protease inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
BRPI0806945A2 (en) 2007-02-01 2014-05-06 Tibotec Pharm Ltd Polymorphic Forms of a HCV MACROCYCLIC INHIBITOR
WO2008095058A1 (en) 2007-02-01 2008-08-07 Taigen Biotechnology Co. Ltd. Hcv protease inhibitors
RU2481340C2 (en) 2007-02-08 2013-05-10 Π’ΠΈΠ±ΠΎΡ‚Π΅ΠΊ Π€Π°Ρ€ΠΌΠ°ΡΡŒΡŽΡ‚ΠΈΠΊΠ°Π»Π· Π›Ρ‚Π΄. Pyrimidine substituted macrocyclic hcv inhibitors
MX2009008541A (en) 2007-02-08 2009-08-18 Tibotec Pharm Ltd Hcv inhibiting macrocyclic phenylcarbamates.
WO2008098368A1 (en) 2007-02-16 2008-08-21 Boehringer Ingelheim International Gmbh Inhibitors of hepatitis c ns3 protease
EA200901101A1 (en) 2007-02-20 2010-04-30 Новартис Аг MACROCYCLIC COMPOUNDS AS INHIBITORS OF HCV PROTEASIS NS3
CA2679377A1 (en) 2007-02-26 2008-09-04 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
WO2008114006A1 (en) 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
WO2008124384A2 (en) 2007-04-03 2008-10-16 Aegerion Pharmaceuticals, Inc. Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
ATE490961T1 (en) 2007-04-24 2010-12-15 Hoffmann La Roche METHOD FOR HCV PROTEASE INHIBITOR INTERMEDIATE
US7906513B2 (en) 2007-04-26 2011-03-15 Enanta Pharmaceuticals, Inc. Hydrazide-containing hepatitis C serine protease inhibitors
US20080267917A1 (en) 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
US8377872B2 (en) 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
US20080279821A1 (en) 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
US20090155209A1 (en) 2007-05-03 2009-06-18 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis c virus replication
EP2185524A1 (en) 2007-05-10 2010-05-19 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
US20090005387A1 (en) 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
AR067180A1 (en) 2007-06-29 2009-09-30 Gilead Sciences Inc ANTIVIRAL COMPOUNDS
WO2009005677A2 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
KR101596524B1 (en) 2007-06-29 2016-02-22 κΈΈλ¦¬μ• λ“œ μ‚¬μ΄μ–Έμ‹œμ¦ˆ, μΈμ½”ν¬λ ˆμ΄ν‹°λ“œ Antiviral compound
JP5433573B2 (en) 2007-07-19 2014-03-05 γ‚€γ‚Ήγƒ†γ‚€γƒγƒ¦γƒΌγƒˆγƒ»γƒ‡γ‚€γƒ»γƒͺチエルケ・デむ・ビγ‚ͺロジを・ヒレコラーレ・ピ・をンジエレツテむ・エツセ・エルレ・エルレ Macrocyclic compounds as antiviral agents
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
WO2009053828A2 (en) 2007-10-22 2009-04-30 Enanta Pharmaceuticals, Inc. P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
US20090111757A1 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8426360B2 (en) 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
KR20100108341A (en) 2007-11-20 2010-10-06 λΈŒλ¦¬μŠ€ν†¨-λ§ˆμ΄μ–΄μŠ€ μŠ€ν… μ»΄νΌλ‹ˆ Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
US8030307B2 (en) 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
CA2708042A1 (en) 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Quinoxalinyl derivatives
WO2009073713A1 (en) 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Oximyl macrocyclic derivatives
US8193346B2 (en) 2007-12-06 2012-06-05 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis C protease inhibitors
BRPI0820733A2 (en) 2007-12-21 2015-06-16 Hoffmann La Roche Process for macrocycle preparation
NZ586231A (en) 2007-12-21 2012-12-21 Avila Therapeutics Inc HCV protease inhibitors comprising a functionalised proline derivative
AU2008340261C1 (en) 2007-12-21 2015-12-10 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
AU2009210789B2 (en) 2008-02-04 2014-01-30 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US20100081713A1 (en) 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
AP2010005416A0 (en) 2008-04-15 2010-10-31 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication.
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2011519943A (en) 2008-05-09 2011-07-14 ベーγƒͺンガー むンゲルハむム γ‚€γƒ³γ‚ΏγƒΌγƒŠγ‚·γƒ§γƒŠγƒ« γ‚²γ‚Όγƒ«γ‚·γƒ£γƒ•γƒˆ γƒŸγƒƒγƒˆ ベシγƒ₯レンクテル ハフツング Method for preparing macrocyclic molecules
US20090285773A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090285774A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (en) 2008-05-16 2012-10-03 ε€ͺζ™―η”Ÿη‰©η§‘ζŠ€θ‚‘δ»½ζœ‰ι™ε…¬εΈ Hcv protease inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009149377A1 (en) 2008-06-05 2009-12-10 Zymogenetics, Llc Use of pegylated type iii interferons for the treatment of hepatitis c
UY31950A (en) 2008-07-01 2010-01-29 Medivir Ab CYCLOPROPIL-POLYMERASE INHIBITORS
KR101647520B1 (en) 2008-08-07 2016-08-10 에프. ν˜Έν”„λ§Œ-라 둜슈 μ•„κ²Œ Process for the preparation of a macrocycle
US8765667B2 (en) 2008-08-20 2014-07-01 Michael Eissenstat HCV protease inhibitors
NZ621143A (en) 2008-09-05 2016-08-26 Celgene Avilomics Res Inc Algorithm for designing irreversible inhibitors
UY32099A (en) * 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
WO2010033466A1 (en) 2008-09-16 2010-03-25 Phenomix Corporation Macrocyclic inhibitors of hepatitis c protease
EP2687526A1 (en) 2008-09-16 2014-01-22 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
MY152824A (en) 2008-09-17 2014-11-28 Boehringer Ingelheim Int Combination of hcv ns3 protease inhibitor with interferon and ribavirin.
US8603737B2 (en) 2008-09-19 2013-12-10 Celgene Avilomics Research, Inc. Methods for identifying HCV protease inhibitors
JP2012502925A (en) 2008-09-23 2012-02-02 ベーγƒͺンガー むンゲルハむム γ‚€γƒ³γ‚ΏγƒΌγƒŠγ‚·γƒ§γƒŠγƒ« γ‚²γ‚Όγƒ«γ‚·γƒ£γƒ•γƒˆ γƒŸγƒƒγƒˆ ベシγƒ₯レンクテル ハフツング Hepatitis C inhibitor compound
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100080770A1 (en) 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI480272B (en) 2008-10-09 2015-04-11 Anadys Pharmaceuticals Inc A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
EP2364159A4 (en) 2008-10-23 2012-06-13 Concert Pharmaceuticals Inc Deuterated macrocyclic inhibitors of viral ns3 protease
US8445430B2 (en) 2008-11-20 2013-05-21 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus
CA2738732A1 (en) 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition of a potent hcv inhibitor for oral administration
US20100272674A1 (en) 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20110114582A (en) 2008-12-19 2011-10-19 κΈΈλ¦¬μ• λ“œ μ‚¬μ΄μ–Έμ‹œμ¦ˆ, μΈμ½”ν¬λ ˆμ΄ν‹°λ“œ Hcv ns3 protease inhibitors
EP2393493A4 (en) 2009-01-30 2013-07-17 Glaxosmithkline Llc Compounds
EP2413955A4 (en) 2009-04-01 2012-12-26 Amylin Pharmaceuticals Inc N-terminus conformationally constrained glp-1 receptor agonist compounds
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
CN102405229A (en) 2009-04-24 2012-04-04 卑θΏͺ拉保ε₯ζœ‰ι™ε…¬εΈ Short-chain peptides as parathyroid hormone (pth) receptor agonist
US20100297079A1 (en) 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
EP2432318A4 (en) 2009-05-22 2012-11-21 Sequoia Pharmaceuticals Inc Bimacrocyclic hcv ns3 protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US20110020272A1 (en) 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
SI2477980T1 (en) 2009-09-15 2017-01-31 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
JP2013511562A (en) 2009-11-24 2013-04-04 ベーγƒͺンガー むンゲルハむム γ‚€γƒ³γ‚ΏγƒΌγƒŠγ‚·γƒ§γƒŠγƒ« γ‚²γ‚Όγƒ«γ‚·γƒ£γƒ•γƒˆ γƒŸγƒƒγƒˆ ベシγƒ₯レンクテル ハフツング Hepatitis C inhibitor compound
WO2011063501A1 (en) 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US20110178107A1 (en) 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
JP5717768B2 (en) * 2010-03-10 2015-05-13 γ‚’γƒƒγƒ΄γ‚£γƒ»γƒγƒγƒžγ‚Ίγƒ»γƒͺγƒŸγƒ†γƒƒγƒ‰ Solid composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2658858A4 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10603318B2 (en) 2012-07-03 2020-03-31 Gilead Pharmasset Llc Inhibitors of hepatitis C virus
US9296782B2 (en) 2012-07-03 2016-03-29 Gilead Sciences, Inc. Inhibitors of hepatitis C virus
US10335409B2 (en) 2012-07-03 2019-07-02 Gilead Pharmasset Llc Inhibitors of hepatitis C virus
US9499550B2 (en) 2012-10-19 2016-11-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9617310B2 (en) 2013-03-15 2017-04-11 Gilead Sciences, Inc. Inhibitors of hepatitis C virus
WO2015038596A1 (en) 2013-09-11 2015-03-19 Emory University Nucleotide and nucleoside compositions and uses related thereto
EP4094767A1 (en) 2013-09-11 2022-11-30 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11820751B2 (en) 2021-01-27 2023-11-21 Vandria Sa Urolithin derivatives and methods of use thereof

Also Published As

Publication number Publication date
WO2012092411A3 (en) 2012-11-08
EA201390988A1 (en) 2014-04-30
US20120295842A1 (en) 2012-11-22
CO6771427A2 (en) 2013-10-15
CN103380132A (en) 2013-10-30
EP2658858A2 (en) 2013-11-06
BR112013016480A2 (en) 2016-09-20
PE20140039A1 (en) 2014-03-01
GT201300172A (en) 2014-10-17
CA2821340A1 (en) 2012-07-05
CN103380132B (en) 2016-08-31
AU2011352145A1 (en) 2013-07-18
ZA201304579B (en) 2014-03-26
SG191759A1 (en) 2013-08-30
ECSP13012791A (en) 2013-09-30
JP2014506255A (en) 2014-03-13
MX2013007698A (en) 2013-08-15
EP2658858A4 (en) 2014-06-25
CR20130341A (en) 2014-01-31
KR20140003521A (en) 2014-01-09
US8951964B2 (en) 2015-02-10

Similar Documents

Publication Publication Date Title
US9309279B2 (en) Macrocyclic hepatitis C serine protease inhibitors
US8951964B2 (en) Phenanthridine macrocyclic hepatitis C serine protease inhibitors
EP2658859A2 (en) Macrocyclic hepatitis c serine protease inhibitors
WO2011156337A2 (en) Macrocyclic hepatitis c serine protease inhibitors
AU2012201327B2 (en) Macrocyclic hepatitis C serine protease inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11853433

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2821340

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 001478-2013

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 2013001907

Country of ref document: CL

Ref document number: 12013501396

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2013547656

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/007698

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: CR2013-000341

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2011352145

Country of ref document: AU

Date of ref document: 20111229

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2011853433

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011853433

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13174830

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20137020148

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201309473

Country of ref document: UA

Ref document number: 201390988

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013016480

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013016480

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130626